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Abstract 
The work presented in this thesis describes the influence of the endothelium on 
smooth muscle cells, and how the structure of the internal elastic lamina (IEL) 
affects this relationship in mesenteric and saphenous arteries. This was enabled 
by the study of functional and confocal microscopy dye transfer experiments. 
Normotensive (WKY) and hypertensive (SHR) rats of 12 weeks and 6 months of 
age were used to assess the effect of hypertension and ageing on endothelial 
and smooth muscle cell communication. 
The endothelium-derived hyperpolarising factor (EDHF) response in mesenteric 
arteries was investigated using wire myography, and the involvement of 
myoendothelial gap junctions (MEGJs) was assessed using the putative gap 
junction inhibitor carbenoxolone. Carbenoxolone attenuated the EDHF response 
in the WKY, suggestive of the involvement of myoendothelial gap junctions in 
EDHF. In the saphenous artery, incubation with L-NAME and indomethacin 
abolished the relaxation to ACh, indicating that there was no EDHF response in 
this artery.  
Dye transfer experiments using luminally loaded calcein-AM and the gap junction 
blocking peptides (GJi) 
37,43Gap27 and 
40Gap27 in mesenteric arteries 
demonstrated that the dye moved from endothelial cells to smooth muscle cells 
by means of gap junctional transfer in the WKY. In the SHR, calcein staining in 
the smooth muscle showed a significant reduction to that observed in the WKY 
at both age points (with endothelial cell staining remaining constant between 
strains), and GJi incubation did not reduce smooth muscle cell staining from that 
of the control. Dye transfer was correlated with the EDHF function of the 
vessels, and was consistent with the increasing evidence supporting the role of 
MEGJS in the EDHF response. No conclusive evidence could be obtained from 
saphenous artery imaging of dye transfer or fenestrae area due to its 
unsuitability for this approach. However, functional experiments illustrated this 
artery (reported to have a lack of MEGJs) to be devoid of an EDHF response, 
thereby making it a potential control artery for the mesenteric artery. 
Differences in the organisation of elastin in the IEL were assessed by 
measurement of fenestrations in the IEL, which are the only points through III 
which endothelial and smooth muscle cells can connect. In WKY, the fenestrae 
appeared to fuse with age, causing a parallel increase in fenestrae area and 
decrease in fenestrae number which was not apparent in the SHR due to the 
inability of fenestrae to fuse in this strain. The smaller fenestrae area in the 6 
month old SHR is thought contribute to the reduced EDHF response compared 
with WKY. 
Collectively, the results of this study imply that there is a relationship between 
the EDHF response and myoendothelial coupling within an artery. EDHF response 
and smooth muscle cell staining following luminal calcein-AM application were 
reduced in the 6 month old SHR compared with aged-matched WKY. The smaller 
fenestrae in the IEL of the 6 month old SHR is a possible explanation as to why 
there is reduced cellular coupling, as this would restrict the passage of 
substances or charge between the endothelium and smooth muscle, be it by gap-
junctional transfer or by diffusion. IV 
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Chapter 1  General Introduction     22 
1.1 Endothelial and smooth muscle cell communication 
Endothelial cells connect with smooth muscle cells through fenestrae in the 
internal elastic lamina (IEL), which is an elastic membrane that separates the 
two vascular layers. These myoendothelial connections are thought to contribute 
to the endothelial control of the smooth muscle cells and hence dilation of the 
vessel. In spontaneously hypertensive rats (SHR) the mesenteric resistance 
arteries have been found to have smaller fenestrae in the IEL compared with the 
WKY normotensive strain (Briones et al., 2003; Gonzalez et al., 2006). It is 
hypothesised that in the SHR the decreased fenestrae size limits the number of 
myoendothelial connections able to form, therefore limiting dilation of the 
resistance arteries and causing an increase in blood pressure. 
1.1.1 Endothelium-Derived Relaxation Factor (EDRF) 
It had long been known that the tone of vascular smooth muscle could be 
influenced by circulating hormones in the bloodstream such as adrenaline, 
angiotensin or vasopressin; or by release of mediators from nerve terminals in 
the arterial wall before it was appreciated that factors released from 
endothelial cells themselves could regulate vessel tone. Prostacyclin was the 
first of these mediators to be found during the study of arachadonic acid 
metabolism in the artery wall (Moncada et al., 1976). The subsequent discovery 
of endothelium-derived relaxation factor (EDRF) in 1980 by Furchgott and 
Zawadzki (Furchgott & Zawadzki, 1980) gave the endothelium an important role 
in vascular physiology, and illustrated that it was not just a passive barrier 
between the plasma and the vessel wall. They found that the endothelium was 
essential in the relaxation of arterial smooth muscle by acetylcholine (ACh), and 
proposed that ACh acted on muscarinic receptors on the endothelial cells to 
stimulate the release of a substance that caused relaxation of the vascular 
smooth muscle. The later discovery that EDRF was nitric oxide (NO) (Palmer et 
al., 1987) is now fundamental to our understanding of blood vessel function with 
the idea that NO release influences blood vessel tone and opposes 
vasoconstriction. Constitutive NO release has been shown to occur in certain 
vascular beds (Martin et al., 1986).  
The biological precursor of NO was established as L-arginine (Palmer et al., 
1988a), an amino acid usually present in excess in the endothelial cytoplasm. An     23 
understanding of the NO pathway made it possible to develop inhibitors of its 
enzymatic generation (Palmer et al., 1988b; Rees et al., 1989; Rees et al., 
1990), including L-NAME and L-NMMA which have come to be commonly used 
experimental tools for excluding nitric oxide synthase (NOS)-derived NO from a 
preparation.  
1.1.2 Mechanism of NO relaxation 
The action of relaxatory substances such as ACh, bradykinin, or substance P on 
receptors on the endothelium causes an increase in intracellular calcium which 
can bind calmodulin to form a calcium-calmodulin complex. This complex is 
capable of converting the nitric oxide synthase (NOS) enzyme from its inactive to 
its active form (Busse & Mulsch, 1990), which converts L-arginine to citrulline 
plus NO in the presence of molecular oxygen and NADPH. The NO produced in 
the endothelial cell then diffuses to the smooth muscle where it binds the haem 
moiety of the basal soluble guanylate cyclase enzyme. This converts the soluble 
guanylate cyclase enzyme to its activated form, which in turn converts GTP to 
cGMP, resulting in relaxation of the smooth muscle (Rapport & Murad, 1983). An 
increase in cGMP in the smooth muscle can result in relaxation by: inhibiting 
calcium entry to the cell, thereby reducing intracellular calcium concentration; 
activating potassium channels causing hyperpolarisation and relaxation; or 
stimulating a cGMP-dependent protein kinase that activates myosin light chain 
phosphatise (Carvajal et al., 2000).  
ACh has been demonstrated to hyperpolarise and relax vascular smooth muscle 
in guinea pig uterine arteries (Tare et al., 1990). This relaxation and 
hyperpolarisation observed was decreased in the presence of L-NAME, which 
showed that NO was capable of hyperpolarising the smooth muscle in this artery. 
In rat middle cerebral arteries, hyperpolarisations to ACh were sensitive to 
glibenclamide, which inhibits ATP-sensitive potassium (KATP) channels (Standen 
et al., 1989). In the rat mesenteric artery, Garland and McPherson showed that 
NO could produce hyperpolarisation which was abolished by glibenclamide, and 
that this was a different mechanism from the hyperpolarising response to ACh, 
which was blocked by a combination of apamin and charybdotoxin (Garland & 
McPherson, 1992). This suggested that the KATP channels located on the smooth     24 
muscle cells were responsible for the NO-induced hyperpolarisation of the 
vascular smooth muscle. 
1.1.3 Endothelium-Derived Hyperpolarising Factor (EDHF) 
The finding that the muscarinic agonist carbachol could hyperpolarise the 
smooth muscle cells of guinea pig mesenteric artery, only when the endothelial 
layer was present, led to the hypothesis that there was a factor released from 
the endothelial cells which had the property of hyperpolarising the smooth 
muscle cells (Bolton et al., 1984). In these experiments the membrane potential 
was recorded in the smooth muscle cells of the small mesenteric artery from 
guinea pig, and changes in artery length were measured on helical strips of 
artery. Carbachol inhibited the shortening of helical strips by noradrenaline or 
raising extracellular potassium concentration, and removal of the endothelium 
abolished this inhibitory effect of carbachol. Removal of the endothelium also 
changed the hyperpolarising response to carbachol observed during control 
conditions to a depolarisation. The hyperpolarisation observed by Bolton and 
colleagues was endothelium-derived, however the phrase endothelium-derived 
hyperpolarising factor was not coined until a later date (Taylor & Weston, 1988). 
It was later found that when NO and prostacyclin production were blocked 
pharmacologically, stimulation of the endothelium by ACh or bradykinin could 
still cause a hyperpolarisation and hence relaxation of vascular myocytes (Chen 
et al., 1988; Taylor & Weston, 1988; Garland & McPherson, 1992). This 
observation provided evidence for the existence of another endothelium-
dependent relaxation factor, distinct from NO and prostacylin, christened 
endothelium-derived hyperpolarising factor (EDHF) due to its hyperpolarising 
effect on the membrane. The cause of this hyperpolarisation which is 
transmitted to the smooth muscle cells from the endothelium has yet to be 
classified, despite extensive research since its discovery, but has been termed 
generally as endothelium-derived hyperpolarising factor (EDHF). There are many 
candidates for EDHF including: potassium ions; hydrogen peroxide; metabolites 
of arachadonic acid; or products of lipoxygenases, to name only a few, but 
agreement over its nature has not been reached and it is now thought that a 
universal EDHF is unlikely.     25 
1.1.4 EDHF Candidates 
1.1.4.1   Potassium ions 
It has been proposed that K
+ efflux through IKCa or SKCa during endothelial 
hyperpolarisation can act directly on adjacent smooth muscle as EDHF and cause 
relaxation, meaning K
+ itself is EDHF. Edwards and colleagues demonstrated that 
EDHF hyperpolarisation of smooth muscle and the subsequent relaxation of small 
resistance arteries (hepatic and mesenteric) in rats were inhibited by a 
combination of ouabain and barium (Ba
2+) (Edwards et al., 1998). Ouabain blocks 
the Na
+/K
+ ATPase, and Ba
2+ blocks inwardly rectifying K
+ channels (KIR) present 
on the smooth muscle cells. The fact that ouabain and Ba
2+ abolish relaxations to 
EDHF and K
+ in rat hepatic artery; and antagonise, but do not abolish, the 
relaxations to EDHF and K
+ in rat mesenteric arteries, supports the theory that 
K
+ is an EDHF in rat arteries. The presence of myoendothelial gap junctions 
(MEGJs) is thought to account for the fact that relaxations were not completely 
abolished in rat mesentery by oubain and Ba
2+. The maximum K
+-induced 
relaxation of endothelium-denuded segments of mesenteric artery in the 
presence of oubain and Ba
2+ was less than when the endothelium was intact, 
probably due to the contribution of MEGJs when the endothelium is intact. The 
mechanism of hyperpolarisation was thought to be related to the opening of 
inwardly rectifying K
+ channels, KIR, (sensitive to Ba
2+) and activating a NA
+/ K
+-
ATPase (sensitive to ouabain). However, contrasting data to this theory was 
found when the EDHF-induced hyperpolarisation of guinea pig internal carotid 
and porcine coronary arteries was not inhibited by a combination of Ba
2+ and 
ouabain (Quignard et al., 1999). Nevertheless, a common feature of the EDHF 
response in all these arteries was its antagonism by the toxin mixture of apamin 
and charybdotoxin. It was found that incubation of the guinea pig internal 
carotid artery with carbenoxolone, a putative gap junction inhibitor, abolished 
the hyperpolarisation to ACh in this artery. This suggested that electronic 
propagation via MEGJs could be the only mechanism underlying the EDHF 
response in the guinea pig internal carotid artery (Edwards et al., 1999), 
confirming that K
+ was not a universal EDHF in all arteries.      26 
1.1.4.2   Hydrogen Peroxide 
Hydrogen peroxide (H2O2) has been shown to be an EDHF in certain vascular 
beds. Catalase, a specific inhibitor of H2O2, inhibits EDHF-mediated relaxations 
and hyperpolarisations in mice mesenteric arteries (Matoba et al., 2000). 
Endothelial Cu,Zn-superoxide (SOD) dismutase plays an important role in the 
synthesis of H2O2 in mesenteric arteries of mice (Faraci & Didion, 2004). It has 
been shown that in Cu,Zn-SOD knockout mice, the EDHF-mediated relaxations 
and hyperpolarisations are reduced in mesenteric arteries and coronary 
microvessels compared with control mice, without a change in the vasodilator 
properties of the smooth muscle (Morikawa et al., 2003). In addition, 
supplements of the SOD mimetic Tempol restored the EDHF-mediated responses 
in these Cu,Zn-SOD knockout mice. Conversely, in isolated guinea-pig carotid 
artery it was found that hyperpolarisation of the vascular smooth muscle was not 
affected by catalase, indicating that hydrogen peroxide is unlikely to contribute 
to EDHF in this artery (Gluais et al., 2005). 
1.1.4.3   Epoxyeicosatrienoic acids 
Epoxyeicosatrienoic acids (EETs) are arachadonic-acid-derived products of 
cytochrome P450 (CYP) epoxygenases which increase the open-state probability 
of BKCa. Most evidence for EETs as EDHF has been obtained from bovine, porcine, 
canine and human coronary arteries (Flemming & Busse, 2006). In bovine 
coronary arteries it was found that the CYP inhibitors SKF 525A and miconazole 
inhibited relaxations and hyperpolarisations to methacholine (Campbell et al., 
1996). These relaxations and hyperpolarisations to methacholine were also 
inhibited by tetraethylammonium (TEA), an inhibitor of calcium-activated 
potassium channels, and by high potassium (20mM). Arachadonic acid relaxed 
precontracted coronary arteries and this was blocked by TEA, charybdotoxin and 
high potassium. 14,15-EET, 11,12-EET, 8,9-EET, and 5,6-EET relaxed 
precontracted coronary arteries and relaxations were attenuated by TEA, 
charybdotoxin and high potassium (Campbell et al., 1996).  A canine in-vivo 
study demonstrated that the epicardial coronary artery dilation induced by ACh 
or arachadonic acid was abolished by a combination of clotrimazole (an inhibitor 
of several isoforms of cytochrome P450 mono-oxygenases) and the nitric oxide 
synthase inhibitor L-NNA, indicating that EETs were an EDHF in this artery in-    27 
vivo. However, EETs are not an EDHF in all arteries; for instance it has been 
shown that EETs are not an EDHF in the rat hepatic artery (Zygmunt et al., 
1996). In these experiments extracellularly-applied EETs did not produce 
relaxation, and 17-Octadecynoic acid (a suicide-substrate inhibitor of the 
cytochrome P450 mono-oxygenases) had no effect on the relaxations mediated 
by EDHF, causing the authors to conclude that EDHF is not an EET in the rat 
hepatic artery. 
1.1.5 Mechanism of EDHF relaxation 
The application of a muscarinic agonist to the endothelium causes a rise in 
endothelial calcium ions (Ca
2+) (Peach et al., 1987) and thus hyperpolarisation 
due to the opening of calcium-activated potassium channels of small (SKCa) and 
intermediate (IKCa) conductance, and efflux of positively charged potassium ions 
from the cell (Edwards et al., 1998). This hyperpolarisation generated in the 
endothelium spreads to the underlying smooth muscle cell layer, by an unknown 
means, and causes dilation of the artery (Busse et al., 2002).  
Voltage sensitive Ca
2+ channels (VSCCs) open during depolarisation of vascular 
smooth muscle and allow entry of extracellular Ca
2+, which subsequently causes 
contraction. Hyperpolarisation of the vascular smooth muscle reduces the 
probability of the voltage-gated Ca
2+ channels being in the open state, thus 
causing a fall in cytoplasmic free Ca
2+ levels, leading to reduced contractility of 
the smooth muscle and hence relaxation (Nelson et al., 1990). It is by these 
means that EDHF causes relaxation of the artery. The endothelium also releases 
a contractile peptide, endothelin, which initiates the opening of voltage-
dependent Ca
2+ channels (Neylon, 1999); therefore EDHF and endothelin may 
operate as physiological antagonists. 
The method by which the EDHF is transmitted from the endothelium to the 
smooth muscle cells is debatable and several methods have been proposed: 
•  Direct cell to cell contact between the endothelial and smooth muscle 
cells exists, through which ions and small molecules (<1 kDa in size) can 
pass. This allows electrical or chemical signals to pass between the 
coupled cells.     28 
•  A substance is released from the endothelial cells, which diffuses to the 
smooth muscle cells. 
The evidence supporting each of these pathways for relaxation varies in each 
part of the vasculature. However, a common feature of an EDHF response is the 
ability to block it with inhibitors of the calcium-activated potassium channels 
located on the endothelial cells (SKCa and IKCa); such as apamin in combination 
with charybdotoxin or TRAM-34 (Garland & McPherson, 1992). 
Apamin is a toxic octadecapeptide that was first isolated from bee venom and 
has been shown to selectively block the SKCa channel (Habermann, 1984). 
Charybdotoxin is a 37 amino acid peptide isolated from the venom of scorpion 
and can inhibit both the intermediate and large conductance calcium-activated 
potassium channels (Garcia et al., 2001). The more recently synthesised TRAM-
34 is a drug that was designed to be a selective inhibitor of IKCa channels (Wulff 
et al., 2000), and is now commonly used in place of charybdotoxin to block 
these channels. 
Stimulation of only a small number of endothelial cells by microionophoresis 
application of ACh caused the whole length of the artery to dilate in the hamster 
cheek pouch microcirculation in vivo (Duling & Berne, 1970), and it has been 
proposed that the mechanism for this phenomenon is the rapid spread of current 
through gap junctions (which is capable of spreading upstream against the 
direction of flow). The increase in intracellular calcium [Ca
2+]i
 in the 
endothelium occurs only in the area stimulated by ACh, whereas the cells along 
the whole arterial length hyperpolarize causing dilation of the entire vessel 
(Dora et al., 2003b; Takano et al., 2004). The spread of this hyperpolarisation 
was not caused by a diffusible factor since: it could be prevented by cutting the 
vessel (Takano et al., 2004); and the time course of spread was at a rate much 
greater than diffusion or other movement of an agent could account for (Duling 
& Berne, 1970). This is suggestive of the propagation being electrical in nature. 
1.1.6 Importance of EDHF increases as vessel size decreases 
Several findings have suggested that communication via gap junctions may be 
most important in vessels where the endothelial: smooth muscle ratio is high     29 
(Berman et al., 2002; Shimokawa et al., 1996a). It has been found that the gap-
junction-dependent component of relaxation is greater in the small mesenteric 
artery relative to aorta (Chaytor, 1998). This would fit physiologically since the 
smaller vessels such as mesenteric resistance arteries are important in 
controlling the total peripheral resistance and hence blood pressure. 
Furthermore, the greater the role of EDHF in vasodilatation of small vessels as 
compared with large vessels raises the possibility that release of EDHF may be 
important in the maintenance of blood pressure. This has been established by 
the findings that SKCa and IKCa knockout mice are hypertensive (Taylor et al., 
2003; SI et al., 2006). In hypertension where there is a loss of EDHF function 
(Goto et al., 2000), the most important sites of loss are at the resistance 
arteries, as this is where a loss of EDHF would be so detrimental to BP control.  
1.1.7 Endothelium-Derived Contractile Factor (EDCF) 
In contrast to NO and EDHF whereby the endothelium exerts a relaxatory effect 
on the underlying smooth muscle cells, the endothelium also releases an 
unknown contractile factor in certain vascular beds (Vanhoutte & Tang, 2008). 
The first observation of EDCF was in isolated veins of the dog, in which 
endothelial cells caused the surrounding smooth muscle to contract in response 
to arachidonic acid and thrombin. This contrasted to the arteries of the same 
preparation where endothelial cells caused a vascular relaxation (De Mey & 
Vanhoutte, 1982). EDCF was also observed in the aorta of the SHR (Luscher & 
Vanhoutte, 1986), in which ACh caused a concentration-dependent increase in 
tone. 
EDCF release is triggered by increases in intracellular calcium, sheer stress, 
muscarinic agonists, and serotonin. The release of EDCF increases in 
hypertension whilst the release of EDHF decreases and this contributes to 
endothelial dysfunction, that is, an upset in the balance of EDHF and EDCF 
(Vanhoutte et al., 2005). EDCF is a product of arachadonic acid metabolism by 
the COX enzyme which is blocked by indomethacin, and has been reported to be 
prostaglandin H2 (PGH2) and prostacyclin acting on the thromboxane-prostanoid 
(TP) receptors on the vascular smooth muscle cells (Vanhoutte & Tang, 2008).     30 
1.2 Myoendothelial Gap Junctions  
Points of direct cell to cell contact between the endothelial and smooth muscle 
cells coupled by a gap junction are termed myoendothelial gap junctions 
(MEGJs). These MEGJs are formed when projections from endothelial cells 
extend through fenestrations in the internal elastic lamina (IEL) and come into 
contact with vascular smooth muscle cells; or less commonly smooth muscle 
cells protrude through the IEL and come into contact with endothelial cells. 
Proteins in the adjacent membranes then connect to form a gap junction. The 
IEL is a layer of elastic tissue that acts as a barrier between the intima and 
media of the vessel, and the fenestrae can be likened to windows through which 
the two cell layers can connect. A myoendothelial bridge (or connection) means 
that the membrane of the endothelial and smooth muscle cell are in close 
apposition but does not strictly mean that the cytoplasm of the cells are coupled 
by a gap junction. It is for this reason that the terminology of myoendothelial 
connections/bridges must not be confused with MEGJs, with the prior meaning 
the protrusion of one cell type through the IEL, and the latter meaning the 
coupling of an EC and SMC via the pore of the gap junction. 
Thoma first found myoendothelial bridges in coronary arteries in 1921, which led 
to the subsequent discovery of myoendothelial bridges in other arteries (Thoma, 
1921). Prior to the identification of gap junctions on myoendothelial bridges it 
was thought that the points of contact between the endothelium and smooth 
muscle might only have provided a structural means of attaching the 
endothelium to the underlying vascular smooth muscle. Spagnoli and colleagues 
(1982) first demonstrated that myoendothelial bridges contained gap junctions: 
cytoplasmic bridges passing through the fenestrae of the IEL of rabbit carotid 
artery were imaged by electron microscopy and it was found that these bridges 
connected the endothelium to the first row of underlying smooth muscle in the 
media of the vessel. Lanthanum hydroxide (an electron dense tracer) permeated 
junctional areas causing pentalaminar patterns that were consistent with gap 
junctional structure (Spagnoli et al., 1982). It was later found that 
heterocellualar junctions formed between cultured layers of aortic endothelial 
and smooth muscle cells, and that cells pre-labelled with [3H]uridine would 
transfer this nucleotide across the heterocellular attachment to the other cell 
population (Davies et al., 1985). Further early evidence supporting the coupling     31 
of EC and SMCs was provided by dye studies, whereby dye was shown to transfer 
from the endothelial to the smooth muscle cell following dye injection by 
microiontophoresis (Little et al., 1995).  
Gap junctions on these myoendothelial projections are termed myoendothelial 
gap junctions and can also be termed heterocellular gap junctions since they 
join two different cell types. Similarly, homocellular gap junctions occur 
between cells of the same type, that is, connecting two endothelial cells or two 
smooth muscle cells (Figueroa & Duling, 2009). The vessel wall contains gap 
junctional communication both within and across the vascular layers, which may 
have a significant role in the co-ordination of conducted vasomotion and 
vascular tone (de Wit et al., 2006).  
1.2.1 Anatomical Evidence of MEGJs 
At the ultrastructural level gap junctions can be identified by an electron-dense 
pentalaminar structure of approximately 10nm in diameter. These 
ultrastructurally identified gap junctions are composed of clusters of gap 
junction channels, varying from a few to thousands of channels in size, and are 
often referred to as gap junctional plaques when viewed with freeze fracture 
techniques or immunohistochemistry (Rummery & Hill, 2009). Anatomical 
evidence for MEGJs is limited, probably due to the small size of these junctions 
and the difficulty in preserving them for analysis.  
MEGJs have recently been observed in mouse mesenteric arteries and it was 
found that all of the MEGJs were located on projections that originated from the 
endothelial cells (Dora et al., 2003a). There is other anatomical evidence of 
MEGJs in different vascular beds including: rat retinal arterioles (Lesson, 1979); 
rat glomerular arterioles (Taugner et al., 1984); rat mesentery (Sandow et al., 
2002; Hill et al., 2002); hamster feed arteries (Sandow et al., 2003; Emerson & 
Segal, 2000); and rat middle cerebral arteries (Sokoya et al., 2006).  
Controversy exists over whether or not electron microscopy images show 
convincing evidence of gap junctions. It is however obvious that cellular 
projections pass through holes in the IEL and come into close apposition with the 
other cell type. It could be argued that even if gap junctions were not present     32 
then the fact that these projections traverse the IEL is important in 
communication between the endothelial and smooth muscle layers. 
1.2.2 Gap junction formation: connexins and connexons 
Gap junctions are formed by the docking of two hemichannels (called 
connexons) at points of cell to cell contact. Each hemichannel is composed of six 
connexin protein subunits and the interdigitation of the extracellular loops of 
opposing connexons creates an aqueous central pore that allows diffusion of ions 
and signalling molecules less than 1 kDa in size between cells (Kumar & Gilula, 
1996). The connexin structure consists of four α-helical membrane-spanning 
domains (M1-M4) with two extracellular loops (E1 and E2). These extracellular 
loops contain highly conserved cysteine residues, which are essential for the 
docking of the two hemichannels (Brink, 1998). Each connexin is named after its 
molecular weight in kDa. There are four connexins (Cx) expressed in the walls of 
blood vessels, namely: Cx37, Cx40, Cx43 and Cx45, and their expression varies 
according to vessel location and species (Figueroa & Duling, 2009). 
Connexins have a half-life of between 1 and 5 hours in cultured cells, meaning 
cellular communication can be modulated by an up- or down-regulation of 
synthesis, assembly, trafficking and degradation (Segretain & Falk, 2004). This 
process can be likened to that of a cell surface receptor’s lifecycle, whereby the 
responsiveness to an agonist can be modulated by receptor up- or down-
regulation or internalisation. The lifetime of a gap junctional plaque may be 
longer than that of the channels of which it is composed (in which the connexons 
have a half life of only 1-5 hours) and new channels have been shown to be 
added to the edges of the plaques whilst old channels are removed from central 
areas (Jordan et al., 2001). 
1.3 Evidence for MEGJs transmitting EDHF 
There is a growing body of evidence suggesting that MEGJs are at least partly, if 
not fully, responsible for transmitting EDHF in certain vascular beds. In order to 
assess the effects of gap junctions on the EDHF response, the building blocks of 
the gap junctions, the connexins, can be disrupted. There are two ways in which 
this can be done: either by using mice in which the gene for a specific connexin     33 
has been knocked out; or by interrupting the gap junction by means of a gap 
junction inhibitor.  
In connexin knockout mice there is a possibility of long-term compensatory 
mechanisms or neonatal lethality, whereas with short term connexin block these 
problems are avoided. However, there are difficulties with gap junction 
inhibitors in that the exact mechanism by which the junction is inhibited is 
unknown and other non-junctional effects have been reported. The putative gap 
junction inhibitor heptanol has been shown to cause hyperpolarisation, a 
decrease in intracellular calcium concentration and a decrease in tension in rat 
mesenteric arteries at low concentrations, and a depolarisation at high 
concentrations, in addition to gap junction inhibition (Matchkov et al., 2004). 
The fact that inhibition of gap junctions results in reduced endothelium-
dependent vasodilatation (Taylor et al., 1998; Goto et al., 2002), coupled with 
the fact that hypertensive mice express a decrease in connexins (Rummery & 
Hill, 2004), and Cx40 knockout mice are hypertensive (de Wit et al., 2000), 
strongly implies that gap junctions are involved in the EDHF response. Also, 
studies examining the incidence of MEGJs in relation to the importance of EDHF 
in a particular vessel have shown that there is a correlation between the two 
(Berman et al., 2002; Shimokawa et al., 1996).     
1.3.1 The EDHF response is dependent on the presence of MEGJs 
in certain vascular beds 
In sandwich preparations, the SMC layer of aorta was separated from the 
underlying endothelium, thus removing any viable MEGJs that may have been 
present. It was found that in this preparation, ACh-induced relaxations of rabbit 
aorta and small mesenteric artery were completely abolished by L-NAME alone 
and no residual relaxation was present, illustrating that the relaxation was 
mediated exclusively by NO (Chaytor et al., 1998a). This preparation 
demonstrates that if the endothelium and smooth muscle are parted, and the 
smooth muscle is then opposed with another sheet of endothelium, that only the 
NO mediated relaxation from the endothelium prevails and EDHF can no longer 
be detected. If EDHF diffused extracellularly then it should transfer from the     34 
endothelium to the smooth muscle in sandwich preparations as NO does. This is 
strongly suggestive of EDHF being transmitted by MEGJs. 
It was demonstrated that in the saphenous artery of juvenile WKY rats, where 
MEGJs were abundant, that ACh evoked a hyperpolarisation and relaxation in the 
presence of L-NAME and idomethacin. However, in the adult rat saphenous 
artery, MEGJs were found to be rare, EDHF-mediated relaxation was absent and 
hyperpolarisations were unstable (Sandow et al., 2004). This would suggest that 
MEGJs have an important role in the saphenous artery in development but are 
not necessary in the adult saphenous artery. It also raises the question as to how 
these gap junctions that were present in the juvenile saphenous artery are no 
longer present in the same artery of the adult. 
Results from the porcine coronary artery showed that non-NO and non-
prostanoid-mediated endothelium-dependent relaxation required functionally 
intact myoendothelial junctions (Kühberger et al., 1994).  
In rat mesentery (where MEGJs are present) the EDHF-mediated relaxation is 
prominent, and in adult rat femoral artery (where no MEGJs are present) there is 
no EDHF-mediated relaxation (Sandow et al., 2002). In this study, stimulation of 
rat mesentery with ACh caused hyperpolarisation of both the endothelial cells 
(EC) and smooth muscle cells (SMC) and pentalaminar MEGJs were found to 
connect the two vascular layers. Conversely, in the femoral artery, stimulation 
by ACh only evoked hyperpolarisation in ECs and not in SMCs, also no MEGJs were 
found to be present (Sandow et al., 2002). In adult rat femoral and saphenous 
arteries only non-junctional projections were present, that is, the endothelial 
cells projected through fenestrae in the IEL but no gap junction was present 
between the membranes of the opposing endothelial and smooth muscle cells; 
and there was a large difference in resting membrane potential of ECs and SMCs 
suggesting an absence of electrical connectivity between the cell layers. The 
endothelial dependent relaxation observed in the femoral artery appeared to 
rely entirely on diffusable NO. Similar resting membrane potentials in ECs and 
SMCs in the mesenteric arteries were thought to be due to the transmission of 
electrical responses by MEGJs.      35 
1.3.2 Gap junction inhibition 
Further evidence for a role of MEGJs in transmitting EDHF has been provided by 
studies using gap junction inhibitors such as Gap 27 and 18α-glycyrrhetinic acid 
(Chaytor et al., 2001; Taylor et al., 1998), whereby inhibition of gap junctions 
has been shown to either significantly reduce or completely abolish the EDHF 
mediated component of relaxation. Gap 27 is a peptide that has sequence 
homology with the extracellular loop 2 of connexin 43 and disrupts gap junction 
function by an unknown mechanism.  
This peptide was found to inhibit relaxation to ACh by around 40% in aorta and 
small mesenteric artery of the rabbit, and also attenuated the endothelium-
dependent component of relaxations to ATP in aorta that were insensitive to L-
NAME. In preparations of denuded endothelium, Gap 27 had no effect on the NO-
mediated relaxation induced by sodium nitroprusside, thus showing that the 
peptide does not interfere with NO-induced relaxation. From these results it was 
concluded that direct cell to cell contact between endothelium and smooth 
muscle contributes to endothelium-dependent relaxations (Chaytor et al, 1998).  
The lack of action of Gap 27 against ACh-induced relaxations in sandwich 
preparations showed that this peptide did not inhibit the synthesis or release of 
NO by the endothelium. These findings suggest that electrical coupling or 
diffusion of a low molecular weight mediator through the MEGJs account for the 
NO-independent component of relaxation, rather than the more traditional view 
of extracellular diffusion of an EDHF (Hutcheson et al., 1999).  
In rabbit iliac artery it has been shown that in the presence of indomethacin, L-
NAME causes a 60-70% reduction in relaxations induced by ACh and cyclopiazonic 
acid (CPA). The L-NAME-insensitive component of relaxations to ACh and CPA 
was attenuated by 18-α glycyrrhetinic acid (18α-GA), an inhibitor of gap 
junctional communication, suggesting that gap junctions are involved in the 
EDHF response in rabbit iliac arteries (Taylor et al., 1998). 
More recent studies have looked at the effects of the gap blocking peptides, 
small peptides designed to interfere with a specific extracellular loop of a 
connexin. Mather at al 2005 developed a new method that loaded connexin-    36 
specific inhibitory molecules into endothelial cells within pressurised mesenteric 
arteries of the rat. This method relied on endocytosis and was achieved by 
changing luminal solution independently of the bathing solution in cycles of 
hypertonic and hypotonic solution. Loading otherwise cell-impermeant 
fluorescent dyes into the endothelial cells via the luminal surface validated this 
technique by demonstrating that uptake did not disrupt the tissue. This method 
of targeting MEGJs by loading putative gap junction blockers through the 
endothelium of intact vessels provided a more precise route for MEGJ blockade 
that did not alter the gap junctional communication within the smooth muscle 
layer. Using this technique in arteries maximally stimulated with phenylephrine 
it was found that the EDHF response was significantly reduced with antibodies 
and mimetic peptides directed against intracellular regions of Cx40 but not Cx37 
or Cx43 (Mather et al., 2005). 
Gap peptides have recently been assessed in human resistance arteries (Lang et 
al., 2007). These resistance arteries were obtained from subcutaneous fat 
biopsies of healthy pregnant women undergoing caesarean. It was found that L-
NAME plus indomethacin reduced the maximal relaxation to bradykinin by 
approximately 50%; and the combination of L-NAME plus indomethacin plus three 
connexin mimetic peptides (
37,43Gap27, 
40Gap27 and 
43Gap26) almost abolished 
relaxations to bradykinin. It should be noted that each gap peptide is 
homologous to a region of the extracellular loop of the connexin whose 
number(s) is denoted by the superscript of its name, and hence this is the 
connexin it “blocks”. In arteries incubated with L-NAME and indomethacin 
neither 
37,43Gap27 or 
40Gap27 alone had a significant effect on bradykinin-
induced relaxation, whereas 
43Gap26 caused marked inhibition that was similar 
to that of the triple combination of connexin mimetic peptides. It was concluded 
that in pregnant women, EDHF-mediated relaxation of subcutaneous resistance 
arteries was dependent on Cx43 and gap junctions. Immunohistochemistry 
demonstrated Cx37, Cx40 and Cx43 expression in the endothelial and vascular 
smooth muscle cells of these human resistance arteries. 
Gap junction blockers added to an organ bath permits them to act on all of the 
specific connexins that they are directed against in the vessel; irrespective of 
whether these connexins are part of a homocellular or heterocellular gap 
junction. This results in a big assumption in that the effects observed are due to     37 
the blockade of these connexins only at the MEGJ (Chaytor et al., 1998a; Dora et 
al., 1999). The gap junction blocker may be exerting effects on the endothelial-
endothelial cell or the smooth muscle cell-smooth muscle cell gap junctions and 
this possibility is not always highlighted in papers using such drugs. In ignoring 
this possibility, authors are inadvertently implying that homocellular coupling is 
not important. 
1.4 Hypertension 
Hypertension is defined as a repeatedly elevated blood pressure exceeding 
140mmHg systolic pressure and 90mmHg diastolic pressure in man (Chobanian et 
al., 2003). It is a risk factor for strokes, heart attacks and arterial aneurysims 
and is a “silent” condition, meaning that symptoms can go unnoticed until a 
major event such as these occur. Around 90-95% of hypertensive patients have 
essential or idiopathic hypertension, which has no known cause. The other less 
commonly diagnosed type of hypertension is secondary hypertension, where high 
blood pressure is a consequence of another condition such as kidney disease or 
an adrenal medulla tumor. Treatment of essential hypertension is symptomatic, 
therefore it is aimed at lowering blood pressure and does not treat the 
underlying cause of the elevated blood pressure. Commonly used drug 
treatments for hypertension include: angiotensin-converting-enzyme inhibitors; 
angiotensin II receptor antagonists; calcium channel blockers; and diuretics 
(Chobanian et al., 2003).  
1.5 Role of gap junctions in hypertension 
Little is known about the role of gap junctions in hypertension. However, from 
their role in the normal physiology of blood vessels it can be postulated that 
their function alters in the hypertensive state, either as a prerequisite to 
elevated blood pressure or as a consequence of elevated pressure. There is 
limited data on the connexin expression in the media of resistance arteries 
during hypertension, however, it has been found that expression of endothelial 
connexons is significantly reduced in SHR caudal and mesenteric arteries as 
compared with the normotensive control rats (Rummery & Hill, 2004). This 
would imply that the limited endothelial connexins in hypertension contributes 
to the elevated pressure.     38 
Genetically modified mice with deletion of specific connexins often die or 
exhibit a compensatory change in the remaining connexins. However, Cx40 
knockout mice have been successfully bred and have been found to be 
hypertensive (de Wit et al., 2000).  
In SHR caudal arteries the density of Cx40 decreases, and in mesenteric arteries 
the density of Cx37 decreases (Kansui et al., 2004; Goto et al., 2000). 
Treatment of high blood pressure with the angiotensin-II receptor antagonist 
candesartan has been found to restore endothelial connexin expression (Kansui 
et al., 2004).  
In mice, neither the deletion of the gene encoding endothelial NOS (eNOS) or 
the inhibition of NOS attenuates agonist-induced vasodilator responses in-vivo 
and in-vitro (in perfused hindlimb) (Brandes et al., 2000), meaning that another 
mechanism must compensate for the lack of NO. eNOS knockout mice were 
shown to be hypertensive compared with wild type controls (Brandes et al., 
2000; Huang et al., 1995), however, the dose dependent decrease in mean 
arterial pressure in response to bradykinin was not significantly different 
between the wild type and eNOS knockout mice (Brandes et al., 2000). It has 
been argued that in mice, EDHF mediated relaxations are equally if not more 
important than endothelium-derived NO in responses to agonist-induced 
endothelium-dependent vasodilatation in resistance arteries (Busse et al., 2002). 
1.6 Structure of the Internal Elastic Lamina 
The IEL of the SHR mesenteric arteries has been found to differ significantly 
from that of the normotensive WKY strain, with the SHR having smaller fenestrae 
in the IEL in adult rats (Gonzalez et al., 2006). It has also been shown that 
spontaneously hypertensive stroke prone rats (SHRSP) have smaller fenestrae in 
the IEL of the carotid artery compared with normotensive controls, due to 
vascular remodelling (Briones et al., 2003). Whether or not this remodelling is a 
consequence of hypertension or is already present and predisposes the SHR to be 
hypertensive remains debatable. It is postulated in this study that the smaller 
fenestrae in the SHR mesenteric arteries restricts the possibility of 
communication of the EDHF, be it electrical or chemical, from the endothelial 
cells to the vascular smooth muscle cells. The myoendothelial bridges may not     39 
be able to traverse the smaller fenestrae and this would lead to a smaller 
number of MEGJs being formed in the SHR, as the fenestrae decrease in size 
with age. This therefore seems a reasonable explanation as to why EDHF 
function decreases with age in the SHR.  
The fenestrae in the IEL have also been studied in rabbit arteries and these data 
show that the IEL was fenestrated at all ages (from 3 to 23 weeks) and the size 
of the fenestrae increased dramatically during postnatal development. The 
estimated number of fenestrae increased per vessel, however fenestrae per mm
2 
decreased by 26%, possibly due to fusing of adjacent fenestrae as they increased 
in size with age (Wong & Langille, 1996). It is thought that the very small 
fenestrae in the immature IEL act as a protective mechanism to counteract the 
high endothelial permeability during development, seen as the IEL presents a 
barrier to transport of substances from the blood and intima to the arterial 
media. Also, the enlargement of the fenestrae during development allows for 
more contact between the endothelium and smooth muscle which is thought to 
cause growth arrest of endothelial cells (Wong & Langille, 1996). 
1.6.1 Influence of Elastin on Vessel Mechanical Properties 
The main constituent of the IEL is elastin. In small arteries such as mesenteric 
artery, elastin is a minor component and is present only in the IEL and discrete 
parts of the media and adventitia. Due to the fact that elastin is scarce in the 
resistance arteries compared with the large conductance vessels, it has been 
misconstrued that elastin has no major role in the small resistance vessels. In rat 
mesenteric resistance arteries the intrinsic stiffness of the vessel has been found 
to decrease with age, and digestion of elastin with pancreatic elastase has been 
found to greatly increase intrinsic wall stiffness since elastin is an important 
determinant of arterial wall distensibility (Briones et al., 2003). Normally elastin 
is only synthesised in embryonic and rapidly developing postnatal tissues. In 
embryonic development, after the mesenchymal cells surrounding the 
endothelial tube differentiate into smooth muscle cells, elastin appears in the 
extracellular matrix between cell layers (Nakamura, 1995). Elastic fibre 
formation then begins with the arrangement of an extracellular microfibrillar 
scaffold where the soluble elastin monomers tropoelastin are deposited (Daga-
Gordini et al., 1987).  It has been shown that in rat blood vessels elastin     40 
increases from the tenth day to the first month of life, and that by 6 months 
there is no further increase in elastin content (Gonzalez et al., 2005). Collagen 
content was also quantified to assess if changes in this caused the decreased 
stiffness of mesenteric arteries with age and it was found that collagen content 
was not modified between one and six months of age in the adventitia or the 
media. These findings led to the conclusion that the decreased intrinsic stiffness 
of the mesenteric arteries between one and six months was not due to a change 
in content of the structural proteins collagen or elastin, but is more likely to be 
due to a reorganization of the arterial wall structure. This same study found that 
in rat MRA the IEL remodelled with age, giving rise to a gradual reduction in the 
thickness of the IEL and a parallel increase in the area occupied by fenestrae. 
These results are consistent with those found in the rabbit carotid artery during 
postnatal development (Wong & Langille, 1996) and suggest that the 
reorganisation of the IEL in rat MRA may be related to a decrease in stiffness 
with age. 
A comparison between the middle cerebral artery (MCA) and mesenteric 
resistance artery, both of which have a similar size of around 250µm internal 
diameter, demonstrates that the differences in elastic properties between these 
arteries is most probably due to their different physiological roles (Briones et 
al., 2003). The media of MCA constricts or relaxes to carefully regulate pressure, 
whereas the mesenteric vessels have a lower degree of myogenic constriction 
and the elasticity of the vessel is more important in regulating vessel 
dimensions. From these observations it is suggested that in resistance arteries, 
the way in which elastin is organised in the IEL may be an important factor in 
the elastic properties of the vessel. It is clear that elastin is an important 
component in determining vessel distensibility, therefore any differences in its 
structural organisation between normotensive and hypertensive rats is a 
worthwhile aspect to study.  
1.7 Relationship between Fenestrae, Myoendothelial 
Bridges and Myoendothelial Gap Junctions 
The studies examining fenestrae in the IEL have not analysed the myoendotheilal 
bridges passing through them. Fenestrae in the IEL are only potential sites for 
MEGJs; therefore assumptions cannot be made about the existence of MEGJs on     41 
projections passing through these fenestrae without physical evidence of the 
junctions themselves. Early electron microscopic studies showing the protrusion 
of either an endothelial cell or smooth muscle cell through the IEL only stain for 
the presence of gap junctions but provide no insight into which connexins make 
up the gap junctional channel (Lesson, 1979; Taugner et al., 1984). A more 
recent study (Sandow et al., 2006b) provided evidence of connexins near the 
sites of fenestrae in the IEL by imaging connexin antibodies using confocal 
microscopy. This combined approach of visualising connexins by antibody 
staining and visualising fenestrae by means of elastin autofluorescence 
simultaneously using confocal microscopy provides a more useful way of studying 
the relationship between fenestrae and gap junctions. When compared at 
different age points for both normotensive and SHR strains, it would be possible 
to compare differences in both fenestrae size and connexin expression to assess 
if there is a change in these parameters with age or between strains.  
As yet, the size of the fenestrae through which the myoendothelial bridges pass 
remains a fairly neglected concept. The smaller size of fenestrae shown to be 
present in the SHR mesenteric arteries as compared with the normotensive 
strain is likely to have functional consequences, whereby it affects the formation 
of connections between the endothelium and smooth muscle cell. This would 
lead to a reduced capacity for the endothelium to hyperpolarize the underlying 
smooth muscle, if the EDHF is indeed transmitted through MEGJs. The aim of this 
study is to establish the correlation between fenestrae size and age in both 
hypertensive (SHR) and normotensive (WKY) rats, to establish if the smaller 
fenestrae size found in the SHR could be a mechanism of reduced EDHF. 
Although the fenestrae in the IEL and the MEGJs have been studied individually, 
very few studies have analysed the relationship between the two structures. It is 
unknown if the projections from the endothelial cell (or very rarely the smooth 
muscle cell) are able to fit through any size of gap in the IEL, or if a smaller size 
of fenestration would prevent the interaction of the two vascular layers. 
The turnover of myoendothelial connections is an important concept about 
which very little is known. A study using dog coronary artery showed that 
myoendothelial contacts decreased with age, with 5.17±0.50, 1.94±0.17, and 
0.33±0.09 contacts observed per 100µm inner circumference of coronary artery     42 
for foetuses, newborns and adults respectively (Kristek & Gerova, 1997). 
However it must be noted that this study quantified only the myoendothelial 
connections and not the myoendothelial gap junctions. It is careless to assume 
that MEGJs are present for every myoendothelial “connection”. However, clearly 
if the myoendothelial bridges are not present then there is no possibility of 
MEGJs forming since MEGJ formation requires the membranes of the endothelial 
and smooth muscle cell to be in close apposition.  
It would be interesting to assess the effect that stress on the artery has on these 
myoendothelial bridges, i.e. does a higher pressure cause the bridges to be 
destroyed. If a vessel was visualised live using confocal microscopy and pressure 
myography then it is feasible that an individual bridge could be examined as the 
pressure was increased, and the resulting fate of the bridge observed.  
To conclude, much work has been done in the field of myoendothelial bridges, 
their associated gap junctions and their involvement in EDHF. However, to date, 
there is a poor understanding of the formation/ lifecycle/ breakage of these 
bridges and their relationship with the fenestrae through which they pass. It is 
postulated that the smaller fenestrae in the IEL of the small mesenteric 
resistance vessels in SHRs may be related to the reduced EDHF in this strain, if 
EDHF is indeed transmitted by MEGJs. This study hopes to contribute to the 
current literature by using both WKY and SHR rats at different age points to 
establish the incidence of myoendothelial bridges and fenestrae size throughout 
development. From this information, inferences can be made about whether a 
loss of EDHF in the SHR with age can be attributed to a decrease in 
myoendothelial connections due to the already known decrease in fenestrae size 
with hypertension. 
1.8 Aims 
The main objectives of this research were: 
(i)  To establish whether differences in WKY and SHR internal elastic 
lamina structure exist by analysing fenestrae area and number.     43 
(ii)  To compare the contractile and relaxant responses in mesenteric and 
saphenous arteries of WKY and SHR rats. 
(iii)  To establish whether there was a relaxant response to ACh which 
persisted following blockade of NO and prostaglandin production in 
mesenteric and saphenous arteries; and to characterise this relaxation 
as an EDHF response using a combination of endothelial cell calcium-
activated K
+ channel blockers. 
(iv)  To investigate the effect of the putative gap junction inhibitor 
carbenoxolone on the EDHF response. 
(v)  To study heterocellular dye transfer on pressure myograph-mounted 
vessels and to assess if this transfer was impeded by gap junction 
blocking peptides. 
(vi)  To investigate connexin location in the mesenteric and saphenous 
arteries of WKY and SHR by means of immunohistochemistry.  
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2.1 Animals used 
Although the focus of this work was to highlight the functional and structural 
differences in the mesenteric vessels of SHR and WKY strains of male rat, 
mesenteric resistance arteries (MRA) were obtained from mice in preliminary 
experiments to test dye suitability and concentrations for confocal work; and to 
perfect the art of myograph mounting small resistance vessels for functional 
work. The mouse mesenteric arteries were obtained from wild type mice used by 
others working in the laboratory. First order mouse and third order rat 
mesenteric arteries were used, both with a similar diameter of around 250 
microns (µm). 
Mesenteric and saphenous arteries were obtained from 12 week old and 6 month 
old WKY (control) and SHR (hypertensive) animals (Table 2.1), killed by carbon 
dioxide overdose. The animals were obtained from Harlan Laboratories (UK) and 
housed in the University Central Research Facility for at least one week prior to 
sacrifice. Housing conditions were: 12 hour light/dark cycle; standard rat feed 
chow; humidity of 45-65%; and temperature 22-25°C.  
Table 2-1 Weight and number of animals used in entire project 
  12 week old  6 month old 
WKY  287 ± 3 (n=24)  367 ± 7 (n=16) 
SHR  283 ± 6 (n=18)  350 ± 7 (n=12) 
Expressed as mean ± SEM in grams 
 
2.2 Dissection 
2.2.1 Mesenteric artery dissection  
The mesenteric arcade was removed after incision of the abdominal cavity to 
expose and open the overlying peritoneum. The gut wall was tied with thread at 
both ends to prevent the propulsion of gut contents into the Petri dish and so 
keep the dissection as clean as possible. The mesentery was then pinned out on 
a Petri dish in ice-cold physiological salt solution (PSS) buffer solution, with the 
gut wall outermost and the arcade branching towards the gut wall from the 
superior mesenteric artery to the third order branches. The first order arteries 
were located with a dissection microscope and identified as those branching 
directly from the superior mesenteric artery. The third order mesenteric vessels     46 
were located as those between the gut wall and the second order vessels in the 
arcade. They were cleaned of surrounding fat with ultra fine forceps, removed 
with small spring scissors, and stored in PSS until use. 
2.2.2 Saphenous artery dissection 
The saphenous vein and artery were identified as those extending distally from 
the femoral vessels branching towards the knee (Figure 2.1). 
 
Figure 2-1 Location of saphenous artery in rodent limb (Zimmermann et al., 2009) 
 
These were removed from the limb together with the adjoining nerve and 
further dissection was performed under a microscope to remove the saphenous 
artery from this section. Care was taken to remove blood from the lumen of the 
arteries without damaging the delicate endothelium. 
2.3 Wire Myography 
Functional experiments to assess the responsiveness of vessels to various 
agonists were performed using a four chamber wire myograph (Danish 
Myotechnology, Aarhus, Denmark). Wire myography is a technique which was 
introduced to study vascular function in-vitro (Mulvany & Halpern, 1977). This 
advanced the study of vessels in organ baths where only larger vessels were used 
due to the mounting procedure not being a viable technique for small resistance     47 
vessels. Wire myography allowed the functional responsiveness of small 
resistance vessels in-vitro to be measured, a technique used in Chapters 4 and 5. 
2.3.1 Vessel mounting 
Following dissection, vessels were cut into 2mm segments and a 40µm stainless 
steel wire was carefully inserted through the vessel lumen using forceps. The 
vessel was then lifted with forceps, using the wire, into the myograph bath, and 
the jaws of the myograph brought together by adjustment of the micrometer to 
secure the wire in position. Metal screws anchored the wire in place and a 
second wire was then inserted through the vessel lumen and secured to the jaws 
in the same way. The fixed head of the myograph was connected to a force 
transducer which recorded the tension across the vessel wall under resting 
conditions and when challenged with various agonists (Figure 2.2).  
 
Figure 2-2 Schematic diagram of myograph bath as viewed from above (reproduced with 
permission of J Morton, 2006 PhD thesis). 
 
A heating element on the base of the myograph warmed the baths to a constant 
temperature of 37°C, and baths were gassed with 95% oxygen/5% carbon 
dioxide. The baths were heated and twenty minutes after a temperature of 37 
degrees was achieved, a resting tension of 0.25 grams force was applied to the 
arteries which were allowed to equilibrate for 30 minutes before the wake-up 
procedure was undertaken. A resting tension of 0.25 grams force was found to 
be optimal for both the third order mesenteric artery and the saphenous artery 
from previous normalisation experiments in the laboratory. Chart software 
(Version 5, ADInstruments, Chalgrove, UK) was used to record experiments and 
measure vessel responses.     48 
2.3.2 Wire Myography Standard Experimental Protocols 
2.3.2.1   Wake up Procedure 
Vessels were equilibrated under tension for 30 minutes and then challenged with 
10µM PE. The contractile response was allowed to plateau before washing with 
heated (37°C) PSS (three 5ml washes three times) over a 15 minute period. A 
second application of 10µM PE was administered 10 minutes after the end of the 
prior washout and a contraction similar in size to the first was obtained in viable 
vessels. To assess endothelial function, ACh was applied to the bath (10µM in 
saphenous, and 3µM in mesenteric) when the second contraction to PE had 
stabilised. Vessels that did not show a suitable relaxation to ACh were excluded 
from any further experimental protocol.  
2.3.2.2   Cumulative Concentration Response Curves  
Cumulative concentration response curves (CCRCs) were obtained by adding 
concentrations of agonist to the bath in half-log molar increments. This was used 
as a standard protocol to assess the response to an agonist since a maximal 
response could be determined from this data. Also, it was possible to calculate 
the pEC50 by means of spreadsheet calculations and so give an indication of the 
sensitivity of the tissue to the agonist. 
2.3.2.3   Time Control Curves 
In experiments where more than one CCRC to an agonist was to be performed a 
time control experiment was run in parallel. The purpose of the time control 
was to ensure that a second CCRC to an agonist could be obtained which did not 
differ significantly from the first.  
2.4 Pressure Myography 
The pressure myograph system used was developed specifically for this project 
and was adapted for use on the confocal microscope. It was based on a model 
used by Dr Kim Dora, after a visit to her laboratory in the University of Bath. It 
consists of two stage-mounted micromanipulators with glass cannulae attached 
for vessel mounting. One of the glass cannulae has tubing connecting it to the 
inflow reservoir, with a small heater in series with the inflow cannula in order to 
warm the incoming solution. The flow and pressure were controlled by a Living     49 
Systems peristaltic pump and pressure servo control. The outflow cannula was 
connected to tubing ending in a three way tap, which when closed permitted the 
maintenance of pressure within the system. The micromanipulators were 
directed into a Warner Instruments RC22 chamber (by use of the X, Y and Z axis 
adjusters), the base of which was a glass coverslip (number 1.5) for confocal 
use. Glass cannulae were made by pulling a thin walled glass cannula using a 
Kopf vertical pipette puller and heat from the metal filament in the puller split 
the cannula into two halves with fine tapered tips. These tips were then snapped 
to size under the microscope with forceps, using another tip to gauge size 
(around 150µm). To remove any ragged edges the tip was flamed with a lighter. 
Tip size was crucial since it had to be greater than 50% of vessel diameter under 
pressure to ensure that the vessel stayed on. Surgical suture was tied in loops 
and placed over the ends of the tips before vessel mounting to allow the vessel 
to be tightly secured (Figure 2.3). The bath was heated by a Warner Instruments 
heat controller, model TC-344B, and filled with MOPS buffer solution to keep pH 
constant at 7.4,  since the bath was not oxygenated.  
                           
Figure 2-3 Rat third order mesenteric vessel mounted on glass tips of pressure myograph, 
pressurised at 70mmHg 
 
The pressure myograph system previously used in the laboratory was designed so 
that the vessel was mounted on and level with the inflow and outflow cannulae. 
This system had a coverslip on top and once inverted, fitted on the confocal 
stage in a similar way to a slide, hence oil-immersion short working length 
objectives were suitable for use with this myograph. In developing the new 
system it was found that the short working length objectives (x20 oil 
WD=0.35mm, and x40 oil WD=0.16mm) were unsuitable, since the vessel could 
not be brought into focus without the objective pushing up the stage and 
breaking the glass cannulae on which the vessel was supported. This was due to     50 
the fact that the glass cannulae approach the bath at an angle, meaning they 
could not come close to the coverslip (base of the bath) without breaking if 
there was any slight upward movement of the bath. To solve this problem new 
long working distance objectives were used (x20 ELWD WD 7.4mm, and x40 
ELWD WD=3.7-2.7mm), which permitted a greater distance between the 
objective lens and the vessel (point of focus). Some other teething problems 
were encountered in developing this system, such as mastering the craft of 
making the glass cannulae, and ensuring that the system was free of any leaks.  
There were several advantages to this new pressure system compared with the 
previous one, namely: 
•  Drugs could be added directly to the bath whilst pressure was maintained, 
allowing cumulative concentration response experiments to be conducted. This 
was not possible in the previous system since the bath was a sealed chamber. 
•  Vessels could be easily imaged before and after incubation of a dye, 
without the need to remove the coverslip before dye addition. This meant that 
progression of staining could be imaged easily, and addition of higher dye 
concentrations caused no disruption to the setup.  
•  The bath could be heated to a physiological temperature, especially 
useful when using dyes requiring esterase activity, such as calcein AM. 
2.4.1 Pressure myograph vessel mounting  
Prior to vessel mounting the pressure lines were filled with room temperature 
MOPS buffer solution to ensure there were no air bubbles in the tubing. The 
vessel was then manoeuvred over the tip of the inflow glass cannula using ultra 
fine forceps and tied on securely with surgical suture. A flow 300 µL/min was 
applied briefly to the vessel to clear the lumen of any blood before the vessel 
was tied on to the outflow cannula. When the vessel was securely tied at both 
ends flow was passed through the system, with the tap at the outflow end open 
to allow the escape of fluid. The tap at the outflow end was then closed to allow 
pressure to be applied to the system and the peristaltic pump was switched from 
flow mode to pressure mode. Pressure was started at 10mmHg and was stepped 
up in 10mmHg intervals over a period of 30 minutes to 70mmHg. To avoid     51 
buckling with increased pressure, the vessel length was adjusted using the 
micromanipulators if necessary without any additional stretching. After this 
equilibration period the vessel was ready for use in the protocol. 
2.4.2 Pressure Fixing of Mesenteric Arteries 
In order to fix a vessel at pressure the vessel was firstly set up on the pressure 
myograph as detailed previously. After the equilibration period the vessel was 
set to the appropriate pressure at which it would be fixed at 37
 oC. The MOPS 
buffer was removed from the bath and replaced with 4% paraformaldehyde for 
one hour. The vessel was removed and stored in 4% paraformaldehyde in a 
refrigerator at 4
oC
 until use. This technique was used in Chapter 3. 
To obtain cross sectional rings of pressure-fixed arteries the vessel was put on a 
slide with a drop of fixative fluid and was cut using a scalpel blade to a ring 
width of approximately 200 µm. A well for the vessel was prepared on another 
slide by an adhesive silicone spacer filled with glycerol. This was important to 
avoid crushing of the ring when the coverslip was applied, which would distort 
its shape. The cut ring was carefully placed inside the well on the slide and 
arranged to view the vessel as a cross-section when looking directly down on the 
slide. A cover slip was placed on top of the adhesive silicone spacer on the slide 
to create a sealed chamber containing the fixed ring.  
2.5 Confocal Microscopy 
Confocal microscopy was developed by Minsky in 1955 and later patented in 
1957. It is based upon the principle that the first objective lens focused a point 
of light at the desired focal plane of the specimen and a second objective lens 
focused the light passing through the specimen with a pinhole at the same focus 
as the first objective lens’ pinhole, hence both lenses were “confocal”. This 
light passing through the specimen and subsequently through the second pinhole 
struck a low noise photomultiplier that generated a signal according to the 
brightness of the specimen. The second objective’s pinhole had the purpose of 
preventing out of focus light from other parts of the specimen above or below 
the plane of interest from reaching the photomultiplier. By these means it was 
possible to collect serial optical sections from thick specimens without having to 
physically section the specimen. Thus structures such as blood vessels could be     52 
imaged intact and a three dimensional image could be reconstructed using a Z-
series (where focal planes are collected at given micron steps in the z-axis to 
collect optical xy “slices” that combine to form a 3D representation of the 
structure). 
In the first confocal systems the beam was kept stationary and the specimen was 
moved on the stage. However, for most modern imaging it is necessary to keep 
the imaged specimen still (as in this work where the vessel was mounted on a 
pressure myograph) and thus more recent microscopes were developed so that 
the specimen remained stationary on the microscope stage and the beam 
scanned across the specimen: hence the name “Laser Scanning Confocal 
Microscopy” (LSCM). 
The confocal microscope used in this study was a Bio-Rad Radience 2100, 
equipped with argon, HeNe and red diode lasers. The confocal objectives used in 
this study had a range of magnifications, numerical apertures (NA) and working 
distances (WD) to suit different experimental methods (Table 2.2). Numerical 
aperture is the most important characteristic defining the performance of an 
objective. The higher the numerical aperture of the objective, the higher the 
resolving power i.e. the power to recognise two discreet points (where the use 
of a lower numerical aperture objective may make these two points appear to 
be merged into one). 
Table 2-2 Numerical aperture and working distance of confocal objectives 
        Numerical  Aperture      Working Distance (mm) 
Nikon Plan Fluor ELWD 40x  0.45  8.1 - 7.0 
Nikon Plan Fluor ELWD 20x  0.6  3.7 - 2.7 
Nikon CFI Plan Fluor 20x oil/water  0.5  2.1 
Nikon CFI Plan Fluor 40x oil  1.3  0.2 
 
2.5.1 Principles of Fluorescence 
Fluorescence requires a source of excitation energy, which in the case of 
confocal microscopy is provided by lasers. Molecules capable of fluorescing are 
termed fluophores and require a wavelength of light near the excitation 
maximum (Em) to induce fluorescence. The Em excites a higher proportion of 
fluophores than any other wavelength of light, and every dye has a 
characteristic range.     53 
 
Figure 2-4 Summary of fluorescence 
(http://probes.invitrogen.com/resources/education/tutorials/1Intro/player.html) 
 
When the fluophore absorbs light energy of a particular wavelength the molecule 
reaches a higher energy (Figure 2.4), or excited, state [1]. The fluophore is 
unstable at this high energy state so it adopts its lowest high energy state which 
is more stable [2]. On return to the most stable “ground state” the fluophore 
releases energy in the form of emitted light [3]. This emitted light is always of a 
lower energy and hence a longer wavelength than the absorbed light due to the 
loss of energy between the higher and lower excited states. 
2.5.2 Approaches to visualising myoendothelial connections 
using laser scanning confocal microscopy 
2.5.2.1   Technical problems 
It was hoped that myoendothelial projections could be viewed in an intact vessel 
on the pressure myograph system using LSCM. Several technical problems were 
encountered in attempting this. Firstly, the oil immersion objectives were not 
compatible with the pressure myograph since the working distance was too small 
to accommodate the space between the vessel and objective. To overcome this 
problem new objectives were purchased with an “extra long working distance” 
(ELWD), allowing the live pressurised vessel to be viewed on the confocal 
microscope. However, at the zoom required to see the IEL in detail there was 
not sufficient definition to make the required measurements. Numerical     54 
aperture had to be compromised for a greater working distance (Table 2.2), and 
this meant poorer resolution. 
The membrane stain FM4-64 was used in live vessels on the pressure myograph in 
an attempt to depict the membrane stained projections traversing the IEL. The 
aim was to image a Z-series of the vessel and then use the 3D image analysis 
software Imaris (Bitplane Scientific Software, Zurich, Switzerland) to slice an 
orthogonal plane, on which the projections would be evident. This would 
advance the technique already established in rings cut from pressure fixed 
vessels (in which membrane stained cellular projections could be seen passing 
through fenestrae in the IEL) and be a more physiological alternative. In 
retrospect this was an ambitious approach to viewing these structures: it was 
found that the fenestrae could not be clearly visualised using the ELWD 
objectives; and that too much fluorescence due to the mass of SMC membranes 
dyed by FM4-64 caused the Z series to be saturated, making it impossible to 
identify defined cell membranes.  All in, this approach was not successful and 
yielded no results.  
The accurate measurement of fenestrae size and number on the live set up was 
not possible due to the lower numerical aperture of the ELWD lenses as 
compared with the oil immersion objectives. This meant that the resolution was 
lower in the ELWD lenses and consequently at the higher zoom needed to 
measure the fenestrae much definition was lost. To test that it was the 
objectives and not just the live set up that were the problem, a fixed vessel was 
slide-mounted and visualised using both the oil-immersion and the ELWD 
objectives. On the oil-immersion objectives clear sharp images were obtained, 
whereas the ELWD objectives gave a blurry undefined image. In light of the oil-
immersion objectives not being suitable for use with the pressure system due to 
impractically small working distances, it was concluded that the fenestrae could 
not be measured on the live vessel as hoped. Instead of measuring fenestrae size 
on the live vessel as pressure was changed, pressure fixed arteries were 
mounted on a slide in order to measure fenestrae size (Chapter 3). 
Another method was devised in an attempt to image the myoendothelial 
projections in the live vessel. Calcein-AM, a cell permeable dye which is taken 
up and converted to its cell impermeable fluorescent form by esterases (Griffith     55 
et al., 2002) was loaded luminally with the proposal of it being taken up by 
endothelial cells and transferred to the smooth muscle cells through MEGJs. Due 
to problems visualising the fenestrae on live vessels on the pressure system it 
was difficult to assess whether cellular projections traversed the fenestrations of 
the IEL. A possible way of solving this was attempted by applying dyes luminally 
in the live vessel and then pressure fixing the vessel after dye application to 
determine whether the dye and fenestrae could be visualised in the fixed vessel 
on a slide with the oil-immersion objective. It was necessary to stain the lamina 
with Alexa 633 hydrazide to view the fenestrae in combination with the calcein 
staining. 
2.5.2.2   Successful approach: Membrane-Stained Fixed Vascular 
Rings 
It was possible to image cellular projections traversing the fenestrae of the IEL 
in cut rings from pressure fixed vessels (Figure 2.5). These images were obtained 
by taking a 10µm deep Z-series through a cut ring, and scanning the Z-series for 
the best plane to view a myoendothelial bridge. This technique was developed 
by Jose Maria Gonzalez (PhD thesis 2004), using the membrane stain FM1-43 FX, 
which has an emission in the same range as the autofluorescent IEL. This meant 
that fenestrae and bridges had to be imaged on separate vessels, with and 
without the membrane dye to view the bridges and lamina respectively. My 
development of this technique using the membrane dye FM4-64 FX allowed for 
simultaneous imaging of the lamina and the membrane stained projections on 
the same vessel (Figure 2.5). Pressure fixed vessels were incubated in a solution 
of 10µM FM4-64 FX in paraformaldehyde for 24 hours before a ring of the vessel 
was cut with a scalpel for imaging. Although this technique was effective for 
visualising the myoendothelial bridges, it gave no indication as to the function or 
the existence of MEGJs, therefore it was decided that dye transfer experiments 
using calcein-AM were more useful to explore the patency of the MEGJs.     56 
 
Figure 2-5 High power view of arterial ring pressure fixed at 70mmHg (40x oil immersion 
objective, zoom 4.5) Image area 64µm x 64 µm. Auto fluorescent elastin is green (B), and 
membrane dye FM4-64 FX is red (C). Colour combine view demonstrates a myoendothelial 
projection traversing a fenestration in the internal elastic lamina (A). 
 
2.6 Immunohistochemistry 
Thin (5µm) transverse sections of mesenteric or saphenous artery were cut using 
a cryostat and stained for the presence of connexins 37 and 43 using 
immunohistochemistry (see Chapter 7 for more detailed methodology).  
Unlabelled primary antibody reacts with the tissue antigen it is specific for, and 
a labelled secondary antibody then binds the primary antibody it is directed 
against. The secondary antibody must be raised against the immunoglobulin of 
the same animal species used in which the primary antibody has been made. 
Secondary antibody can be tagged with a fluophore to produce fluorescence on 
binding of the primary antibody; or it can be labelled with an enzyme such as 
horseradish peroxidise which reacts with 3,3’-diaminobenzidine (DAB) to 
produce a brown precipitate stain wherever the primary and secondary antibody 
are attached (Ramos-Vara, 2005). Both fluorescently labelled secondary 
antibodies and the DAB staining method were utilised in this study (Chapter 7). 
To assess the presence of Cx37 in the vessel, Cx37 mouse monoclonal primary 
antibody (1:200) was used with a goat anti-mouse conjugated alexa 488 
secondary antibody. To assess the presence of Cx43 in the vessel, Cx43 rabbit     57 
polyclonal primary antibody (1:100) was used with a goat anti-rabbit conjugated 
alexa 546 secondary antibody. 
2.7 Data Analysis 
2.7.1 Wire Myography Results 
The individual measurements from each bath were pooled to calculate the mean 
and standard error of the mean for each data set, where n denotes the number 
of animals used and N represents the total number of replicates.  
Results were expressed in either grams tension (g), which is the value of the 
myograph response after subtraction of baseline tension; or as a percentage of a 
response. To calculate the EC50, that is, the concentration of agonist required to 
obtain half the maximal response, it was necessary to express the data as a 
percentage of the response being assessed. In the case of PE, each response in 
the CCRC was expressed as a percentage of the maximum contraction in grams 
obtained during the curve. 
In calculation of pEC50 values for ACh the situation was more complex since the 
CCRC was performed on a stable preconstriction to PE, and the size of this 
preconstriction varied considerably between strains. In order to normalise for 
this difference in PE contraction, the ACh relaxation was expressed as a 
percentage of the PE preconstriction in grams rather than as a percentage of its 
own maximum relaxation in grams. A value of near 100% relaxation in this case 
would equate to almost a full reversal of the PE mediated contraction, and so 
this was more informative than simply expressing the points on the curve as a 
percentage of the maximal ACh induced relaxation in grams; since a value of 
100% here would only indicate the greatest relaxation had been achieved but not 
necessarily a full reversal of the PE induced contraction. 
2.7.2 Confocal Microscopy Results 
In an attempt to quantify observations made by eye from the images captured 
on the confocal microscope it was necessary to devise methods of quantitative 
analysis. Three imaging programs were used for this purpose, namely: Imaris 
(Version 5.1: Bitplane Scientific Software, Zurich, Switzerland); Amira (Version     58 
3.2: Visage Imaging, Berlin, Germany); and Metamorph (Version 6.1: Molecular 
Devices, Wokingham, UK). Each image was composed of pixels, or in the case of 
three dimensional Z-series stacks- voxels. The brightness of these pixels or 
voxels lay on the 8 bit scale of 1 to 255; with 255 being the brightest value, and 
1 the least intense. By differentiating voxels or pixels by brightness, it was 
possible in some cases to depict patterns in an image or to depict specific 
structures (in the case of fenestrations in the IEL which show up as dark patched 
against the bright auto-fluorescence of the IEL) and thresholding functions could 
be utilised. The method by which the images were analysed will be referred to 
in more detail in the appropriate confocal chapters. 
2.7.3 Statistics 
All statistical analysis was performed using Graph Pad Prism software (Version 
5). Two groups were compared using paired or unpaired Student’s t-test. More 
than two groups with one variable were compared using one way analysis of 
variance (ANOVA). More than two groups with two variables were analysed using 
two way analysis of variance (ANOVA). If differences were detected by ANOVA, 
individual groups were compared with the use of Bonferroni post-tests for all 
pairwise comparisons. Statistical significance was classified as p values less than 
0.05, as is standard practice in scientific papers. The number of animals used 
was denoted by n. 
2.8 Solutions and Drugs 
For wire myography experiments Physiological Salt Solution (PSS) of the 
following composition (mM) was used: NaCl 118.4, KCl 4.7, CaCl2 2.5, KH2PO4 
1.2, MgSO4 1.2, NaHCO3 25 and glucose 11.1, bubbled with 95% O2/5% O2 to pH 
7.4 at 37
0C. 
For experiments on the pressure myograph, MOPS-buffer of the following 
composition (mM) was used:
 145 NaCl, 4.7 KCl, 2.0 CaCl2·2H2O, 1.17 MgSO4·7H2O,
 
2.00 MOPS, 1.2 NaH2PO4·H2O, 5.0 glucose, 2.0 pyruvate
 (Na salt), 0.02 EDTA free 
acid, 2.75 NaOH. This solution was adjusted to pH 7.4 ± 0.02 at 37°C by addition 
of 10M NaOH or HCl.     59 
The drugs/compounds and method used to dissolve them are detailed (Table 
2.3). Compounds dissolved in solvents were made at a higher concentration than 
required and diluted in distilled water or MOPS to minimise the effect of the 
solvent on the experiment.  
Table 2-3 Drugs/compounds, suppliers and solvents used to dissolve. 
Drug/compound 
 
Supplier  Solvent for stock 
     
Phenylephrine hydrochloride 
 
Sigma  Distilled water  
Acetylcholine chloride 
 
Sigma  Distilled water 
L-NAME (N
ω-nitro-L-arginine 
methylester)
 
 
Sigma  Distilled water 
Indomethacin 
 
Sigma  Ethanol (100%) 
Carbenoxolone 
 
Sigma  Distilled water 
Apamin  Tocris 
 
Distilled water 
TRAM-34 
 
Tocris 
 
DMSO 
FM4-64 FX 
 
Invitrogen  DMSO 
Calcein-AM  Invitrogen/C300MP  100mM in DMSO then 
dilution to 3µM in MOPS 
 
40Gap27  Severn Biotech 
 
Distilled water then 
dilution in MOPS 
 
37,43Gap27  Severn Biotech  Distilled water then 
dilution in MOPS 
     
Cx37 mouse monoclonal 
 
Alpha Diagnostics 
 
PBS (1 in 200) 
     
Cx43 rabbit polyclonal 
 
Millipore  PBS (1 in 100) 
 
 
          
 
 
 
Chapter 3  Vessel Morphometry     61 
3.1 Introduction 
It is well established that the SHR blood vessel structure varies from that of the 
WKY; either as a consequence of or as a pre-requisite to elevated blood pressure 
(Heagerty et al., 1993; Mulvany et al., 1996; Gonzalez et al., 2006; Arribas et 
al., 1997), with a thickening of the media and alterations in elastin layout 
reported.  
Elastin content and the layout of fenestrae have previously been studied in 
mesenteric arteries in our laboratory. It was found that there was no difference 
in elastin content between 1 and 6 month old WKY rats, but fenestrae area 
increased with age (Gonzalez et al., 2005); and that SHR had an impairment of 
fenestrae enlargement throughout the first month of life, resulting in smaller 
fenestrae than those of the 1 month old WKY rats (Gonzalez et al., 2006). There 
have been similar findings in the rabbit carotid artery in which fenestrae area 
increased with age from 3 to 23 weeks (Wong & Langille, 1996). 
Since it was not possible to acquire blood pressure measurements from the 
animals used, one of the aims of this chapter was to assess the differences in 
arterial dimensions between the strains. This was intended to confirm that the 
SHR strain were indeed hypertensive since they would be expected to have an 
increased wall thickness compared with the WKY. Mesenteric arteries from SHR 
have been shown to have a thicker media than normotensive controls, without a 
significant increase in cross-sectional vessel area, thus implying that the 
increased wall thickness was a consequence of vascular remodelling (Mulvany et 
al., 1985; Qiu et al., 1995; Gonzalez et al., 2006).  
Fenestrae size and number was measured in each strain to correlate this with: 
previous work from the laboratory; the transfer of luminally loaded dye (Chapter 
5); and the functional EDHF response (Chapters 3 and 4). Fenestrae area had 
been studied extensively in the previous papers from the laboratory therefore 
only a small sample size was assessed in this study. 
3.1.1 Aims 
The aims of this chapter were:     62 
•  To compare arterial measurements in 12 week and 6 month old WKY and SHR 
to assess vascular remodelling with ageing or hypertension. 
•  To measure fenestrae size and number in 12 week and 6 month old WKY and 
SHR. 
3.2 Methods 
3.2.1 Arterial dimensions 
Measurements were made on live pressure myograph-mounted vessels (mounting 
procedure detailed in Chapter 2). Pressure diameter curves were obtained using 
Vediview software and a microscope-mounted camera to track the vessel walls 
(Figure 3.1). This allowed for inner and outer diameter; wall thickness; 
wall/lumen ratios; and cross sectional area to be calculated for each artery over 
intraluminal pressures ranging from 10 to 70mmHg. Intraluminal pressure was 
increased in 10mmHg steps at 5 minute intervals. 
 
Figure 3-1 Screenshot of Vediview software user interface tracking dimensions of 12 week 
old WKY pressurised mesenteric artery 
 
3.2.2 Fenestrae analysis 
Fenestrae were imaged from pressure-fixed (70mmHg) slide-mounted vessels. 
The protocol for pressure-fixing arteries was detailed in the General Methods 
chapter (Chapter 2). Pressure fixed vessels were viewed using a x40 oil 
immersion objective at a zoom of 4.5 (giving an image area of 64µm x64µm or 
4096µm
2) and captured with a 3 frame Kalman. Elastin autofluorescence was     63 
excited at 488 nm, and laser and gain settings were increased until fluorescence 
of the internal elastic lamina was at an optimal level.  Metamorph imaging 
software (Version 6.1) was used to analyse the images. The original image 
underwent a 3x3 lowpass which was thresholded to select dark objects, i.e. the 
fenestrae (Figure 3.2). A size threshold range of between 0.5 and 300µm
2 for 
fenestrae area was implemented, to exclude any particularly small or large dark 
spots. Each of the green patches was counted as an object, with the orange 
patches included in the thresholding for dark objects but excluded from 
measurement by size. The number and area of fenestrae for each image were 
stored in a data log in Metamorph and exported to Excel (Microsoft Office 2003). 
     
Figure 3-2 Left hand pane showing original image, right hand pane showing thresholded 
measured objects on lowpass version of image (green included, orange excluded from 
count). 
 
Mean data for inner and outer diameter; wall thickness; wall/lumen ratios; and 
cross sectional area were compared between strains at each pressure using an 
unpaired t-test. Fenestrae area and number were compared between strains and 
ages using unpaired t-tests. 
3.3 Results 
3.3.1 Arterial dimensions 
Mesenteric vessel measurements showed that there was no significant difference 
in outer vessel diameter between age-matched WKY and SHR (Figures 3.3 and 
3.4), and lumen diameter was not significantly different between age-matched 
WKY and SHR (Figures 3.5 and 3.6). Similarly, cross-sectional area did not vary     64 
between WKY and SHR of the same age (Figure 3.8), with the exception of the 
12 week old rats at 10mmHg (Figure 3.7). The 12 week old SHR had a 
significantly thicker wall than the 12 week old WKY at intraluminal pressures of 
30, 60 and 70mmHg (Figure 3.7), and the 6 month old SHR had a significantly 
thicker wall than the age-matched WKY at 40 and 70mmHg (Figure 3.8). The 
wall: lumen ratio was significantly greater in the SHR compared with the WKY 
at: 50, 60 and 70mmHg in the 12 week old; and at 10, 30 and 70mmHg in the 6 
month old animals (Figures 3.11 and 3.12). 
In the WKY, outer vessel diameter increased significantly from the 12 week old 
to the 6 month old at pressures 10, 20 and 30mmHg (P<0.05). The SHR outer 
diameter did not vary with age at any intraluminal pressure. There were no 
significant increases in lumen diameter in either strain with age. Cross sectional 
area was significantly increased in the 6 month old WKY compared with the 12 
week old WKY at intraluminal pressures 10, 20 and 30mmHg (p<0.05). In the 
SHR, the only significant increase in cross sectional area between the 12 week 
old and 6 month old was at 40mmHg (p<0.05). Wall thickness significantly 
increased with age in the WKY at intraluminal pressures of 60 and 70mmHg. SHR 
wall thickness significantly increased with age in the SHR at 10 and 70mmHg. 
The wall to lumen ratio did not differ significantly between the 12 week old and 
the 6 month old WKY. However, the wall to lumen ratio was increased in the 6 
month old SHR compared with the 12 week old SHR at an intraluminal pressure 
of 70mmHg (p<0.05).     65 
 
Figure 3-3 Pressure diameter curve for outer vessel diameter at pressures ranging from 10 
to 70 mmHg in 12 week old third order mesenteric arteries (n=6) 
 
 
Figure 3-4 Pressure diameter curve for outer vessel diameter at pressures ranging from 10 
to 70 mmHg in 6 month old third order mesenteric arteries (WKY n=6, SHR n=3) 
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Figure 3-5 Pressure diameter curve for lumen diameter at pressures ranging from 10 to 70 
mmHg in 12 week old third order mesenteric arteries (n=6) 
 
 
Figure 3-6 Pressure diameter curve for lumen diameter at pressures ranging from 10 to 70 
mmHg in third order mesenteric arteries (WKY n=6, SHR n=3) 
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Figure 3-7 Pressure curve for cross sectional area at pressures ranging from 10 to 70 mmHg 
in 12 week old third order mesenteric arteries (n=6). *p<0.05 compared with WKY 
 
 
Figure 3-8 Pressure curve for cross sectional area at pressures ranging from 10 to 70 mmHg 
in 6 month old third order mesenteric arteries (WKY n=6, SHR n=3).  
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Figure 3-9 Pressure curve for wall thickness at pressures ranging from 10 to 70 mmHg in 12 
week old third order mesenteric arteries (n=6). *p<0.05 compared with WKY. 
 
 
Figure 3-10 Pressure curve for wall thickness at pressures ranging from 10 to 70 mmHg in 6 
month old third order mesenteric arteries (WKY n=6, SHR n=3). * p<0.05 compared with 
WKY. 
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Figure 3-11 Pressure curve for wall/lumen ratio at pressures ranging from 10 to 70 mmHg in 
12 week old third order mesenteric arteries (n=2). **p<0.01 compared with WKY. 
 
 
Figure 3-12 Pressure curve for wall/lumen ratio at pressures ranging from 10 to 70 mmHg in 
6 month old third order mesenteric arteries (WKY n=6, SHR n=3). *p<0.05 compared with 
WKY. 
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3.3.2 Fenestrae analysis 
Images of fenestrae in the IEL of 12 week and 6 month old WKY and SHR are 
shown (Figures 3.13 and 3.14 respectively). Analysis of fenestrae area (Figure 
3.15) showed that there was no significant difference between fenestrae area of 
the two strains at 12 weeks of age, but that the 6 month old WKY had 
significantly larger fenestrae than the 6 month old SHR. There was no significant 
increase in fenestrae area with age in the SHR, however, fenestrae area 
increased significantly between 12 weeks and 6 months in the WKY.     71 
12 week old WKY         12 week old SHR 
 
             
 
     
 
     
Figure 3-13 Images of IEL from pressure fixed (70mmHg) arteries of 12 week old WKY (n=2, 
left hand pane) and SHR (n=2, right hand pane).  
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6 month old WKY        6 month old SHR 
 
     
 
     
 
     
Figure 3-14 Images of IEL from pressure fixed (70mmHg) arteries of 12 week old WKY (n=2, 
left hand pane) and SHR (n=2, right hand pane).      73 
 
Figure 3-15 Fenestrae area in 12 week and 6 month old WKY (n=2) and SHR (n=2) animals. 
Expressed as mean ± SEM. *** p<0.001 compared with 12 week old WKY, 
$$$ p<0.001 
compared with 6 month old WKY.
 
 
The 12 week old SHR had significantly less fenestrae than the 12 week old WKY, 
but there was no significant difference in fenestrae number between the strains 
at 6 months of age. The 6 month old WKY had significantly less fenestrae than 
the 12 week old WKY, however there was no significant difference in fenestrae 
number between the 12 week and 6 month old SHR (Figure 3.16) 
 
Figure 3-16 Number of fenestrae in 12 week and 6 month old WKY (n=2) and SHR (n=2) 
animals. Expressed as mean ± SEM in µm
2. * p<0.05 compared with 12 week old WKY 
 
3.4 Discussion 
There was no significant difference in outer vessel diameter between aged 
matched WKY and SHR, which implies that any differences observed in wall 
thickness or lumen diameter were a result of inward remodelling in the SHR. A     74 
small sample size of only three for the 6 month old SHR may explain why some 
results did not reach statistical significance.  
Since the vessels from the pressure diameter curves were later used in other 
protocols at 70mmHg they were not inflated above this pressure to avoid 
stretching. These data may have been more informative if the curves were 
continued to higher pressures where significant differences between the strains 
may have become apparent. Nevertheless, vessel dimensions at 6 months of age 
were analogous with those of Briones et al. (2003).  
In the WKY, fenestrae number decreased with age, whilst fenestrae area 
increased. This was suggestive of the fusing of adjacent fenestrae during vessel 
growth. In the 6 month old WKY fenestrae do appear to be less distinct than 
those of the 6 month old SHR, with a slight “webbed” appearance which may be 
due to the joining of several smaller fenestrae to form a larger one. The 
appearance of the fenestrae was similar to that observed by Briones et al. (2003) 
in the 6 month old WKY and SHR. This theory of enlarging fenestrae was 
consistent with Wong and Langille (1996), where they state that fenestrae 
frequently fuse with neighbouring fenestrae in the rabbit carotid artery; and 
that fenestrae size increased with age between the 30 day old and the adult 
rabbit.  In the SHR this fusing did not appear to occur, and indeed fenestrae area 
or number did not differ significantly with age in this strain. Fenestrae area of 
the 6 month old WKY and SHR in this study was comparable to Gonzalez et al. 
(2006). It may be that an inability of the fenestrae to fuse in the SHR strain 
could account for the decreased fenestrae area compared to the WKY at 6 
months of age.  
A study looking at the elastin content in small mesenteric arteries from 6 month 
old WKY and SHR rats showed that although fenestrae were smaller in the SHR, 
the amount of elastin did not differ between the strains (Briones et al., 2003). It 
has also been shown that elastin content increased from the tenth day to the 
first month of life, with no further increase in the elastin content of the 
mesenteric arteries by 6 months of age (Gonzalez et al., 2005). Elastin is 
reported to be synthesised only in embryonic and developing tissues, and in the 
vasculature the synthesis was at a maximum at the perinatal period (Davis, 
1995). This was supported by the elastic laminae being completely formed by     75 
four weeks of postnatal age in rat aorta (Gerrity & Cliff, 1975). Furthermore, 
elastin synthesis was found to be negligible in mature animals and mRNA levels 
for elastin were absent in the bovine aorta (Marriencheck et al., 1995). In light 
of these data, the smaller fenestrae seen in the 6 month old SHR compared with 
the 6 month old WKY in the present study could be a result of the reorganisation 
of the elastin fibres rather than an increase in the production of elastin in the 
hypertensive strain. Gonzalez et al. (2006) also report a parallel reduction in IEL 
thickness and increase in fenestrae area with age in the WKY, which further 
suggests the elastin in the artery is able to adapt to changes in vessel diameter 
by remodelling. Vascular remodelling has been shown to involve either; an 
increase (hypertrophy); decrease (hypotrophy); or a rearrangement (eutrophy) 
of the vacular wall components (Mulvany et al., 1996). In these terms, elastin 
eutrophy appears to contribute to vascular remodelling in the 6 month old SHR. 
Vascular remodelling is associated with altered mechanical properties and SHR 
had greater intrinsic wall stiffness than WKY from 30 days onwards (Gonzalez et 
al., 2006). It has been shown that elastase (which degraded elastin in a 
concentration dependent manner) incubation can abolish the structural and 
mechanical differences between the strains (Briones et al., 2003) which suggests 
that the structural differences in elastin organisation are at least partly 
responsible for the increased wall stiffness in the SHR.  
There was no significant difference between the strains in terms of fenestrae 
area at 12 weeks of age. However, at 6 months of age, SHR were shown to have 
smaller fenestrae than age-matched WKY. It is possible that if the SHR vessels 
are under higher pressure than WKY physiologically then fixing them at a higher 
pressure more representative of their physiological value would increase the 
fenestrae area to a size similar to that observed in the WKY. It would be 
interesting to pressure-fix SHR vessels at a higher pressure to determine how this 
affected fenestrae area and also the number of fenestrae observed per image, 
i.e. do the fenestrae become bigger and sparser if the artery expands. 
Comparison of the fenestrae area in the literature varies, which is likely due to 
differences in the methodology of pressure fixing. Some papers have stated that 
vessels were dilated by the addition of compounds such as sodium nitrite or     76 
sodium nitroprusside (Sandow et al., 2009), or by the omission of calcium from 
the PSS (Briones et al., 2003). 
In addition to gap junctions, potassium channels have also been localised to 
fenestrae in the IEL of mesenteric vessels (Sandow et al., 2006a; Dora et al., 
2008). This raises the possibility that there would be less opportunity for 
potassium channels to be involved in vasodilatation in the SHR, in which there 
are smaller fenestrae compared with WKY at 6 months of age. As yet, potassium 
channels at the IEL have not been studied in the SHR. 
There was difficulty in obtaining images of the saphenous IEL due to thickness of 
the vessel wall. The pressure-fixed saphenous artery was sliced open with a 
scalpel and flattened on a slide in an attempt to obtain a better view of the IEL 
but the fenestrae were still unclear. In retrospect it may have been possible to 
image the IEL of this vessel whilst it was still mounted on the pressure 
myograph. 
The presence of fenestrae was not always accompanied by a traversing cellular 
projection, however, the existence of the gap in the IEL may still be important 
in the diffusion of substances between endothelial and smooth muscle cell layers 
via a low resistance pathway. This has been studied previously in our laboratory 
(Gonzalez, unpublished) with results showing that 73% of fenestrae contained a 
projection in the WKY and only 40% in the SHR. This study imaged IEL and 
membrane projections separately due to fluorescence being in the same 
channel, therefore in the present study techniques were established to examine 
the cellular projections simultaneously to the fenestrae (Chapter 2, Figure 1.5), 
although this work was not pursued further due to time limitations. 
A possible consequence of the reduced fenestrae area in the 6 month old SHR 
could be a restriction of the passage of cellular projections from the endothelial 
to smooth muscle cells, or conversely from smooth muscle to endothelial cells. If 
MEGJs located at the end of these cellular projections were to be involved in the 
EDHF response as reported (Chaytor et al., 2001; Dora et al., 2003a; Edwards et 
al., 1999; Kühberger et al., 1994) then this reduced fenestrae area in the 6 
month old SHR as compared with the 6 month old WKY could account for the 
reduced EDHF response in the 6 month old SHR.          
 
 
 
Chapter 4                                                   
Functional responses of third order mesenteric 
arteries from young and old WKY and SHR rats 78 
4.1 Introduction 
Third order mesenteric arteries (MRAs) in the rat are generally recognised as 
resistance arteries due to their small diameter of less than 400 microns, and 
their anatomical position at the end of a branching arcade which offers a high 
resistance pathway to the arterial blood passing through. EDHF is known to have 
an increasingly important role with decreasing vessel size (Chaytor et al., 1998b; 
Shimokawa et al., 1996b; Berman et al., 2002; Berman et al., 2002) and so rat 
third order MRAs were chosen in this study to establish EDHF function in the 
normotensive and hypertensive strains, to correlate this with the transfer of 
luminally loaded dye (Chapter 6). Additionally, the effect of age was studied 
since EDHF function is known to be impaired in ageing as well as in hypertension 
(Fujii et al., 1993).  
Much of the literature comparing WKY and SHR strains focuses surprisingly on 
larger vessels and not specifically on the resistance arteries which are thought to 
be most important in determining peripheral blood pressure. This may be due to 
the fact that organ baths were used to perform the experiments and the 
common usage of wire myographs, which are required for the study of very small 
resistance vessels, did not start until a later date, meaning that larger vessels 
were used due to a limitation of equipment available at the time. 
It is well established that SHR has a greater contraction to adrenergic agonists 
than WKY (Mulvany & Halpern, 1977; Li et al., 2007; Takata & Kato, 1995). This 
makes sense physiologically if an increased peripheral resistance occurs as a 
result of decreased lumen diameter and the SHR has a greater capacity for 
vascular constriction. However, the increased tone of SHR is not only due to the 
increased efficacy of adrenergic agonists, but is also a consequence of 
endothelial dysfunction (Vanhoutte, 1996). Jointly, this increase in contractility 
and decreased ability to relax is a major problem in blood pressure regulation in 
hypertension. The purpose of this chapter was to elucidate the vascular function 
of third order mesenteric vessels from young (12 week old) and old (6 month old) 
normotensive and hypertensive rats. 
Arterial relaxations elicited by ACh are now known to involve different 
endothelium-derived factors. NO was established as an endothelium derived 79 
relaxing factor by Moncada’s group (Palmer et al., 1987) following Furchgott and 
Zawadzki’s observation that the endothelium was essential in ACh-mediated 
relaxations of isolated rabbit arteries (Furchgott & Zawadzki, 1980). Moncada’s 
group also devised compounds inhibiting the synthesis of NO (Rees et al., 1990), 
tools which consequently revealed NO was not the only factor causing an ACh-
induced vascular relaxation in certain vessels. It was discovered that a factor 
other than NO was responsible for the hyperpolarisation to ACh in the rat small 
mesenteric artery (Garland & McPherson, 1992). Products of the cyclooxygenase 
(COX) pathway of arachadonic acid metabolism, for example, prostacyclin were 
also found to be involved in the relaxant response in certain vessels including 
bovine coronary artery and rabbit mesenteric artery (Bunting et al., 1976; 
Dusting et al., 1977).  
In the presence of a combination of L-NAME and indomethacin (to block NO and 
prostacylin respectively), a relaxation to ACh still occurred. This factor released 
from the endothelium hyperpolarised the smooth muscle cells and so was termed 
EDHF. EDHF is known to be markedly reduced in the SHR mesenteric arteries 
compared with WKY controls (Fujii et al., 1992), and in vessels such as third 
order mesenteric where the majority of the ACh-induced relaxation is accounted 
for by EDHF, this could be detrimental to blood pressure control. In addition to 
this, vessels from the SHR have been shown to release EDCF (Luscher & 
Vanhoutte, 1986; Rapoport & Williams, 1996; Luscher et al., 1990). An 
imbalance in the release of EDHF and EDCF which act as physiological 
antagonists is thought to account for the endothelial dysfunction in this strain 
(Luscher, 1990; Vanhoutte, 1996). 
The aim of this chapter was to assess the differing contribution of each of these 
endothelium-derived factors in response to ACh in third order vessels from young 
(12 weeks) and old (6 month) WKY and SHR rats. Since relaxations and not 
membrane potential was measured it was necessary to assume that a relaxation 
elicited by ACh in the presence of L-NAME and indomethacin was an EDHF 
response: even though the actual hyperpolarisation could not be measured, the 
relaxation observed was presumed to be a measure of the hyperpolarising effect 
on the vessel mechanics. This was further clarified by the use of a high 
potassium concentration to prevent the hyperpolarising response. 80 
4.1.1 Aims 
The aims of this chapter were: 
•  To compare the PE and ACh response of 3
rd order mesenteric arteries from 
normotensive and hypertensive rats and assess the effect of ageing on this 
response within strains. 
•  To compare the ACh response following incubation with L-NAME and 
indomethacin with that of the control in WKY and SHR at 12 weeks and 6 
months of age. 
•  To assess the effect of the putative gap junction inhibitor carbenoxolone on 
the relaxation to ACh alone, and in combination with L-NAME and 
indomethacin. 
•  To establish if the ACh relaxant response observed following L-NAME and 
indomethacin incubation was representative of an EDHF response. 
 
4.2 Methods 
Third order mesenteric resistance vessels were myograph mounted as detailed in 
the General Methods (Chapter 2). Thirty minutes after the wake up procedure 
CCRCs to PE were constructed. After the return to baseline from washout of the 
PE curve a rest period of 30 minutes elapsed before an ACh CCRC was 
constructed. All ACh CCRCs were performed against a stable plateau of 
preconstriction of the artery with 10µM PE.  
In a series of experiments examining the effects of endothelial factors, 100µM L-
NAME and 10µM indomethacin; 10µM indomethacin; or 100µM carbenoxolone 
were incubated 40 minutes prior to the ACh CCRC. 30µM apamin and 1µM TRAM-
34 were incubated for 1 hour prior to the ACh CCRC. 
Mean data for PE-induced contraction and ACh-induced responses were 
compared using Student’s t-tests or one-way ANOVA, with the use of Bonferroni 
post-tests for all pairwise comparisons. 81 
4.3 Results 
4.3.1 PE induced contraction 
Concentration dependent contractions were produced to PE in third order MRAs 
from WKY and SHR strains to assess the contractile responses. Representative 
traces of PE CCRCs are provided (Figures 4.1 and 4.2). 
 
Figure 4-1 Cumulative concentration response curve to PE in 3
rd order MRA of 6 month old 
WKY (expressed in grams tension). 
 
 
Figure 4-2 Cumulative concentration response curve to PE in 3
rd order MRA of 6 month old 
SHR (expressed in grams tension). 
 
At both age points the SHR had a significantly greater maximum response to PE 
than WKY. Also, for each strain, the maximum responses to PE were significantly 82 
higher in the 6 month old than in the 12 week old animals (Figure 4.3 and Table 
4.1). There was no significant difference in the pEC50 values for PE between 
either of the strains or ages (Table 4.1), suggesting that the sensitivity to PE was 
the same in all the animals tested (Figure 4.4). 
 
Figure 4-3 Cumulative concentration response curves to PE in 3
rd order MRAs of 12 week 
and 6 month old male WKY and SHR (12 week: WKY n=6; SHR n=8; and 6 month: WKY n=5, 
SHR n=6). Expressed as mean ± S.E.M in grams tension. 
 
Table 4-1 Maximum response and pEC50 of PE in 3rd order MRAs of 12 week and 6 month 
old WKY and SHR.  
  WKY  SHR 
PE  12 week  6 month  12 week  6 month 
Emax (g)  0.75 ± 0.07
¥¥¥  1.01 ± 0.08
*  1.14 ± 0.09**   1.57 ± 0.14
††¤ 
pEC50  5.65 ± 0.11   5.721 ± 0.06  5.70 ± 0.08   5.78 ± 0.07 
Expressed as mean ± S.E.M. (12 week: WKY n=6; SHR n=8; and 6 month: WKY n=5, SHR 
n=6). 
* p<0.05; **p<0.01 compared with 12 week old WKY (unpaired t-test). 
††  p<0.01 compared with 6 month old WKY (unpaired t-test). 
¥¥¥ p<0.001 compared with 6 month old SHR (unpaired t-test). 
¤ p<0.5 compared with 12 week old SHR (unpaired t-test). 
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Figure 4-4 Cumulative concentration response curves to PE in 3
rd order MRAs of WKY and 
SHR (12 week: WKY n=6; SHR n=8; and 6 month: WKY n=5, SHR n=6). Expressed as a % of 
own maximum PE response obtained during CCRC, as mean ± S.E.M. 
 
4.3.2 ACh induced responses 
Responses to ACh were obtained by means of a concentration response curve 
following stable preconstriction with PE. Third order MRAs were precontracted 
with 10µM PE in order to establish a maintained constriction of the vessel upon 
which concentration dependent relaxations to ACh could be assessed. 
Representative traces of 12 week old WKY and SHR ACh CCRCs are provided 
(Figures 4.5 and 4.6 respectively). 
 
Figure 4-5 Trace of 12 week old SHR contraction after application of 10µM PE and 
subsequent ACh CCRC (expressed in grams tension). 84 
 
Figure 4-6 Trace of 12 week old SHR contraction after application of 10µM PE and 
subsequent ACh CCRC. Representative of 4 out of 6 experiments (expressed in grams 
tension). 
 
Due to unstable PE preconstrictions in the 12 week SHR strain (Figure 4.5), there 
is a small sample size of only two animals for ACh induced relaxations. After a 
series of experiments challenging the 12 week old SHR mesenteric vessels with 
other agonists such as 5-HT and U-46619 in an attempt to gain a stable 
contractile baseline these preparations were discarded due to the spasmodic 
nature of the responses, since any relaxations produced by ACh could not be 
distinguished from the unstable nature of the pre-constriction.  From six 
preparations tested (each with 4 replicates on the myograph) in the 12 week old 
SHR, a stable baseline could only be achieved in two of these experiments. 
In order to make comparisons between the ACh responses in the two strains it 
was necessary to express the data as a percentage of the PE preconstriction, 
since the PE contractile responses in WKY and SHR differed (Table 4.1). 
Expressing the ACh relaxation as a percentage of PE-induced preconstriction is 
more indicative of the reversal of the PE induced tone than merely expressing it 
in grams, and it normalises the data between strains to take account of the 
greater PE response in the SHR. 
For completeness the pEC50 for ACh was expressed as a percentage of its own 
maximum relaxation (where 100% of its own response was always achieved) and 85 
as a percentage of PE preconstriction (where a full reversal of the PE-induced 
tone was not necessarily achieved). It was shown that there was no significant 
difference in each group between pEC50 values calculated by either method 
(Table 4.2), and for this reason any further pEC50 values shown were calculated 
only as a percentage of the PE preconstriction. 
Table 4-2 Maximum relaxation and pEC50 of ACh in 3
rd order MRAs of 12 week and 6 month 
old WKY and SHR 
  WKY  SHR 
ACh  12 weeks  6 months  12 weeks  6 months 
Emax (g)  -0.64 ± 0.05  -0.98 ± 0.08*  -1.07 ± 0.27  -1.18 ± 0.10 
Emax (% PE)      97.78 ± 0.88  96.06 ± 1.45  91.23 ± 6.28  85.66 ± 4.39 
pEC50 (% own max)   7.62 ± 0.13  7.67 ± 0.11   7.23 ± 0.40  7.62 ± 0.17 
pEC50 (% PE)   7.53 ±0.09  7.76 ± 0.13   6.95 ± 0.36  7.51 ± 0.17 
Expressed as mean ± S.E.M in grams tension and as a percentage relaxation of PE-induced 
contraction. (12 week: WKY n=4; SHR n=2; and 6 month: WKY n=5, SHR n=6). 
*p<0.05 compared with 12 week old WKY (unpaired t-test). 
 
The pEC50 of ACh was not significantly different between strains at 12 weeks of 
age (Table 4.2). Also, the maximum response to ACh, normalised for both strains 
as a percentage relaxation of the PE induced contraction, was not significantly 
different between the strains at 12 weeks. In terms of grams relaxation, SHR had 
a greater response than WKY at 12 weeks (although this was not statistically 
significant), most likely due to the fact that it had a far greater contractile 
response to PE from the outset and therefore has a greater capacity for 
relaxation. However, this 12 week SHR data must be interpreted with caution 
since the ACh data has a small sample size of only two, with the other four 
experiments discarded due to an unstable preconstriction to PE. This implies 
that the data from the two experiments analysed may not be a fair 
representation of the 12 week old SHR’s response to ACh. 86 
 
Figure 4-7 Cumulative concentration response curves to ACh in 3rd order MRAs of WKY 
and SHR. (12 week: WKY n=4; SHR n=2; and 6 month: WKY n=5, SHR n=6). Expressed as 
mean ± S.E.M in grams tension. 
 
 
Figure 4-8 Cumulative concentration response curves to ACh in 3rd order MRAs of WKY 
and SHR. (12 week: WKY n=4; SHR n=2; and 6 month: WKY n=5, SHR n=6). Expressed as 
mean ± S.E.M as a % of PE preconstriction. 
 
6 month WKY and SHR show very different profiles in their response to 
cumulative concentrations of ACh, although there was no significant difference 
in their pEC50 values. The 6 month old WKY showed a steady decrease in tension 
until a maximal relaxation of near 100% was achieved, thus almost fully reversing 
the PE induced contraction (Table 4.2). However, the 6 month old SHR reacted 
very differently with an “upshoot” in the CCRC following maximal relaxation at 
concentrations of ACh greater than 3µM (Figures 4.7 and 4.8).  
4.3.2.1   ACh Time Control CCRCs 
Time control curves showed that there was no desensitisation of the tissue to 
ACh and so any differences shown on a second curve following incubation with a 
drug were a true effect of the drug. Time control curves for 12 week old WKY, 6 87 
month old WKY, and 6 month old SHR strains (Figure 4.9, 4.10 and 4.11 
respectively) showed that there was no significant difference between the first 
and second ACh curves (Tables 4.3, 4.4 and 4.5 respectively), indicating that 
there was no desensitisation of the tissue. Since only one time control curve was 
able to be performed for the 12 week old SHR it was not possible to mean the 
data to calculate an accurate pEC50 or maximum relaxation for 1
st and 2
nd curves 
in this strain. 
 
Figure 4-9 Comparison of ACh response for control and time control CCRC in 3
rd order 
MRAs of 12 week old WKY (n=5). Response expressed as % relaxation of PE preconstriction 
mean ± S.E.M. 
 
Table 4-3 Comparison of ACh response for control and time control CCRCs in 3
rd order 
MRAs of 12 week old WKY.  
ACh  1
st curve  2
nd curve 
Emax (% PE)  96.31 ± 2.47  96.50 ± 1.37 
pEC50 (% PE)   7.51 ± 0.18   7.28 ± 0.18 
Expressed as mean ± S.E.M as a percentage relaxation of PE-induced contraction (n=5). 88 
 
Figure 4-10 Comparison of ACh response for control and time control CCRC in 3
rd order 
MRAs of 12 week old WKY (n=5). Response expressed as % relaxation of PE preconstriction 
mean ± S.E.M. 
 
Table 4-4 Comparison of ACh response for control and time control CCRCs in 3
rd order 
MRAs of 6 month old WKY.  
ACh  1
st curve  2
nd curve 
Emax (% PE)  89.52 ± 5.43  81.66 ± 10.51 
pEC50 (% PE)   7.42 ± 0.15   6.99 ± 0.32 
Expressed as mean ± S.E.M as a percentage relaxation of PE-induced contraction (n=5). 
 
Figure 4-11 Comparison of ACh response for control and time control CCRC in 3
rd order 
MRAs of 6 month old SHR (n=5). Response expressed as % relaxation of PE preconstriction 
mean ± S.E.M. 
 
Table 4-5 Comparison of ACh response for control and time control CCRCs in 3
rd order 
MRAs of 6 month old SHR. 
ACh  1
st curve  2
nd curve 
Emax (% PE)  85.27 ± 9.34  82.90 ± 10.29 
pEC50 (% PE)   7.85 ± 0.32   7.77 ± 0.42 
Expressed as mean ± S.E.M as a percentage relaxation of PE-induced contraction (n=5). 89 
4.3.3 Responses to ACh following incubation with agents 
affecting endothelial factors 
Further ACh responses were assessed after incubation with compounds affecting 
various endothelium derived factors to gain a better insight into the mechanisms 
of the ACh response. Due to the unstable nature of the 12 week old SHR 
preconstrictions it was not possible to examine the effects of all the compounds 
on endothelial function in this strain- in the two experiments where stable 
preconstrictions were maintained the EDHF response was assessed. 
4.3.3.1   L-NAME and indomethacin incubation 
ACh CCRCs were obtained in 12 week and 6 month old third order mesenteric 
vessels with a stable PE-induced preconstriction (Figures 4.12 and 4.13 
respectively) following L-NAME and indomethacin incubation to block the 
production of NO and prostaglandins.  
 
Figure 4-12 Cumulative concentration response curves to ACh following 40 min 100µM L-
NAME and 10µM indomethacin incubation in 3rd order MRAs of 12 week old male WKY (n=5) 
and SHR (n=2). Response expressed as % relaxation of PE preconstriction mean ± S.E.M. 
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Figure 4-13 Cumulative concentration response curves to ACh following 40 min 100µM L-
NAME and 10µM indomethacin incubation in 3rd order MRAs of 6 month old male WKY (n=5) 
and SHR (n=6). Response expressed as % relaxation of PE preconstriction mean ± S.E.M. 
 
It was not possible to calculate an accurate pEC50 for ACh in the SHR following L-
NAME and indomethacin incubation at either age point since there was 
practically no relaxant response. Incubation with L-NAME and indomethacin 
significantly reduced the maximum ACh-induced relaxation in both the 12 week 
and 6 month old SHR compared with control data (Tables 4.6 and 4.7). 
In the WKY, incubation with L-NAME and indomethacin reduced the maximum 
ACh-induced relaxation in the 12 week old but did not significantly alter the 
relaxation compared with the control data in the 6 month old (Tables 4.6 and 
4.7). The pEC50 was significantly decreased in the 12 week and 6 month old WKY 
(Tables 4.6 and 4.7) following incubation with L-NAME and indomethacin, thus 
indicating a decrease in sensitivity to ACh. 
4.3.3.2   Indomethacin incubation 
Further experiments were undertaken to assess the effects of incubating 
indomethacin alone in 12 week old and 6 month old rats (Figure 4.11 and 4.12 
respectively). This left the NO component of relaxation intact and removed the 
COX-mediated component of the ACh response. 91 
 
Figure 4-14 Cumulative concentration response curve to ACh following 40 min 10µM 
indomethacin incubation in 3rd order MRAs of 12 week old male WKY (n=5). Response 
expressed as % relaxation of PE preconstriction mean ± S.E.M. 
 
Figure 4-15 Cumulative concentration response curves to ACh following 40 min 10µM 
indomethacin incubation in 3rd order MRAs of 6 month old male WKY (n=5) and SHR (n=5). 
Response expressed as % relaxation of PE preconstriction mean ± S.E.M. 
 
In the 12 week old WKY indomethacin did not significantly alter the maximum 
ACh-induced relaxation or the pEC50 of ACh as compared with control data 
(Table 4.6). In the 6 month old animals, indomethacin incubation meant the SHR 
relaxation had the same profile as the WKY (Figure 4.12), and removed the 
secondary increase in tension to ACh seen under control conditions. However, 
incubation with indomethacin did not alter the sensitivity to ACh in either strain 
(Table 4.7). 92 
4.3.3.3   Carbenoxolone incubation 
The effect of carbenoxolone on ACh mediated responses in third order 
mesenteric vessels of 12 week and 6 month old WKY and SHR was assessed 
(Figures 4.13 and 4.14 respectively). 
 
Figure 4-16 Cumulative concentration response curves to ACh following 40 min 100µM 
carbenoxolone incubation in 3rd order MRAs of 12 week old male WKY (n=5). Response 
expressed as % relaxation of PE preconstriction mean ± S.E.M. 
 
Figure 4-17 Cumulative concentration response curves to ACh following 40 min 100µM 
carbenoxolone incubation in 3rd order MRAs of 6 month old male WKY (n=5) and SHR (n=5). 
Response expressed as % relaxation of PE preconstriction, mean ± S.E.M. 
 
In the 12 week old WKY and both strains at 6 months carbenoxolone did not 
affect the ACh-induced relaxant response in terms of efficacy or sensitivity since 
there was no significant difference between maximum relaxations and pEC50s in 
vessels under control conditions and following incubation with carbenoxolone 93 
(Table 4.6 and Table 4.7). Carbenoxolone incubation abolished the secondary 
increase in tension seen in the 6 month SHR control (Table 4.7). 
4.3.3.4   Carbenoxolone incubation in the presence of L-NAME and 
indomethacin 
Since carbenoxolone did not significantly alter the maximum relaxation or the 
sensitivity to ACh in the mesenteric arteries of either strain or age, it was tested 
in combination with L-NAME and indomethacin to remove the contribution of NO 
or prostanoids. This was only performed in the 12 week old WKY due to animal 
availability (Figure 4.15). 
 
Figure 4-18 Cumulative concentration response curves to ACh following 40 min 100µM L-
NAME and 10µM indomethacin incubation in control, and +300µL carbenoxolone in 3rd 
order MRAs of 12 week old male WKY (n=4). Response expressed as % relaxation of PE 
preconstriction mean ± S.E.M. 
 
Carbenoxolone incubated in combination with L-NAME and indomethacin 
significantly reduced the maximum relaxation to ACh in the 12 week old WKY 
(Table 4.6).    94 
Table 4-6 Summary of ACh induced responses in 12 week old WKY and SHR 3
rd order mesenteric arteries following incubation with agents  
affecting endothelium derived factors.  
 
12 week old 
  Relaxation to ACh 
 
      n  Emax (% of PE)    pEC50   
Increase in 
tension to 
ACh 
WKY         
   Control  5        97.82 ± 1.51  7.48 ± 0.25  No  
 + L-NAME and 
indomethacin 
 
5        85.17 ± 7.73
††  6.88 ± 0.31  No 
   Control  5  94.18 ± 4.28  7.74 ± 0.33  No 
+ indomethacin 
 
5  94.52 ± 2.81  7.47 ± 0.20  No 
   Control  5  98.92 ± 0.71  7.43 ± 0.07  No 
+carbenoxolone 
 
5  93.22 ± 3.43  7.47 ± 0.25  No 
 
   Control  4  97.51 ± 1.73  7.84 ± 0.17  No 
  + L-NAME,   
indomethacin and  
carbenoxolone 
 
 
4 
 
      42.98 ± 10.18*** 
 
 
 
- 
 
No 
SHR         
   Control  2   91.23 ± 6.28  7.23 ± 0.39  No 
 + L-NAME and 
indomethacin 
2      5.50 ± 4.19
◊◊◊  -  No 
 
   
   
Relaxations  expressed as % relaxation of PE preconstriction, mean ± S.E.M in %, and pEC50 as mean ± S.E.M. 
††p<0.001 (unpaired t-test) compared with SHR + L-NAME and indomethacin, 
◊◊◊ p<0.0001 compared with control, *** p<0.0001 compared 
with control (1 way-ANOVA).     95 
Table 4-7 Summary of ACh induced responses in 6 month old WKY and SHR 3
rd order mesenteric arteries following incubation with agents 
affecting endothelium derived factors.  
 
6 month old 
  Relaxation to ACh 
 
      n  Emax (% of PE)    pEC50   
Increase in 
tension to 
ACh 
WKY         
   Control  5      96.57 ± 2.09  7.87 ± 0.23  No  
 + L-NAME and 
indomethacin 
 
5  96.70 ± 5.25
◊◊  7.04 ± 0.18  No 
   Control  5  99.15 ± 0.31   7.74 ± 0.33  No 
+ indomethacin 
 
5  98.32 ± 0.42  7.86 ± 0.42  No 
   Control  5  96.43 ± 2.29  7.98 ± 0.26  No 
+carbenoxolone 
 
5  97.41 ± 0.89  8.22 ± 0.15  No 
SHR         
   Control  6  88.68 ± 5.34  7.81 ± 0.18  Yes 
 + L-NAME and 
indomethacin 
 
6     30.58 ± 9.61***  -  No 
   Control  5      93.10 ± 2.90  6.82 ± 0.51  Yes 
+ indomethacin 
 
5    94.91 ± 3.39
†††  7.52 ± 0.44  No 
   Control  5  93.57 ± 3.23  7.62 ± 0.33  Yes 
+carbenoxolone  5      92.79 ± 2.64
$$$  7.64 ± 0.53  No 
 
Relaxations expressed as % relaxation of PE preconstriction, mean ± S.E.M in %, and pEC50 as mean ± S.E.M. 
***p<0.0001 compared with control (1 way-ANOVA). 
††† p<0.0001 (1 way-ANOVA); 
$$$ p<0.0001 (1 way-ANOVA); 
◊◊ p<0.001 (unpaired t-test) compared with SHR + L-NAME and indomethacin .         
4.3.4 Further examination of responses to PE in 12 week old SHR 
(following incubation with indomethacin or carbenoxolone) 
In order to gain a better understanding of the unstable nature of the PE response 
in the 12 week old SHR mesenteric vessels a series of experiments was 
performed to assess the effects of indomethacin and carbenoxolone individually 
on a CCRC to PE. Indomethacin blocks the COX enzyme which is known to be 
involved in the production of EDCF by acting on arachadonic acid. 
Time control experiments were performed to ensure there was no 
desensitisation to PE on the second curve (Figure 4.15). There was no difference 
in sensitivity or efficacy of PE in the first and second curves (Table 4.8). 
 
Figure 4-19 Cumulative concentration response curves to PE in 3
rd order MRAs of 12 week 
old SHR (n=4). Expressed as a % of maximum PE response obtained during 1st CCRC as 
mean ± S.E.M. 
 
Table 4-8 Maximum response and pEC50 of PE in 1
st and 2
nd curves of 3rd order MRAs of 12 
week old SHR.  
PE         1
st curve  2
nd curve 
E max (% PE)
       100 ± 0.00
       92.07 ± 5.737 
pEC50        5.94 ± 0.32      6.07 ± 0.287 
Expressed as % of maximum PE response obtained during 1st CCRC as mean ± S.E.M (n=4). 
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Figure 4-20 Cumulative concentration response curves to PE following 40 min 10µM 
indomethacin incubation (n=4). Expressed as a % of maximum PE response obtained during 
control CCRC as mean ± S.E.M. 
 
Table 4-9 Maximum response and pEC50 of PE in 3rd order MRAs of 12 week old SHR.  
PE      Control     Indomethacin 
E max (% PE)
   100 ± 0.00
       74.24 ± 5.15** 
pEC50    5.72 ± 0.18     5.24 ± 0.07
† 
Expressed as % of maximum PE response obtained during 1st CCRC as mean ± S.E.M (n=4). 
† p<0.05, **p<0.001 paired t-test compared with control. 
 
Figure 4.17 showed that incubation with indomethacin prior to the PE CCRC 
caused a significant decrease in the maximum response and decreased the 
sensitivity of the tissue compared with the control (Table 4.9). In contrast, 
Figure 4.18 showed that incubation with carbenoxolone prior to the PE CCRC did 
not affect PE efficacy or sensitivity (Table 4.10). 
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Figure 4-21 Cumulative concentration response curves to PE following 40 min 100µM 
carbenoxolone incubation. Expressed as a % of maximum PE response obtained during 
control CCRC as mean ± S.E.M (n=4). 
 
Table 4-10 Maximum response and pEC50 of PE in 3rd order MRAs of 12 week old SHR.  
PE      Control    Carbenoxolone 
E max (% PE)
    100 ± 0.00
        97.75 ± 23.35 
pEC50    5.85 ± 0.22      5.49 ± 0.13
 
Expressed as % of maximum PE response obtained during 1st CCRC as mean ± S.E.M (n=4). 
 
4.3.5 Hyperpolarisation of Endothelial Cells 
Since facilities were not available to measure the cell membrane potential, 
further experiments were performed to determine if the relaxation observed in 
the presence of L-NAME and indomethacin was in fact representative of an 
endothelial hyperpolarisation spreading to the smooth muscle cells. This was 
done by adding high potassium (30mM KCl) to the myograph bath and then 
adding cumulative concentrations of PE to achieve the same level of 
preconstriction as in the L-NAME and indomethacin curve. A CCRC to ACh was 
then performed upon this preconstriction (Figure 4.19). It was found that after 
the vessel was exposed to 30mM KCl there was no longer a relaxation observed 
in the CCRC to ACh (Figure 4.20). The addition of KCl to the preparation caused 
a small contraction in response to concentrations of ACh above 10 µm (Table 
4.11) as opposed to the near full relaxation observed under control conditions.     99 
 
Figure 4-22 Representative trace of mesenteric vessel from 12 week old WKY after exposure 
to 30mM KCl then addition of PE to preconstrict vessel prior to ACh CCRC. 
 
 
Figure 4-23 Cumulative concentration response curves to ACh following 40 min 100µM L-
NAME and 10µM indomethacin incubation: control vessels pre-constricted with 10µM PE; 
and vessels exposed to 30mM KCl prior to ACh CCRC (n=2) 
 
Table 4-11 Maximum relaxation and pEC50 of ACh in 3rd order MRAs of 12 week old WKY 
control (constricted with PE) and KCl (constricted with 30mM KCl prior to further PE pre-
constriction). 
ACh      Control  KCl 
E max (% PE)
   97.04 ± 1.83
  -22.06 ± 1.70*** 
pEC50  7.54 ± 0.12  -
 
Expressed as a % of PE preconstriction as mean ± S.E.M (n=2). 
***p<0.001 paired t-test compared with control.     100 
4.3.6 Evidence that the relaxation to ACh  following incubation of 
L-NAME and indomethacin is an EDHF response 
It is well documented that the relaxant response persisting in the presence of L-
NAME + indomethacin is an EDHF-mediated response. To confirm that this was 
the case in these particular experiments, blockers of the small and intermediate 
calcium-activated potassium channels (SKCa and IKCa respectively) located on the 
endothelium were employed to prevent the hyperpolarisation of the endothelial 
cells upon ACh application (Figure 4.21). The SKCa and IKCa channel blockers 
apamin and TRAM-34 used in combination significantly reduced the relaxation 
which persisted in the presence of L-NAME and indomethacin in the 12 week old 
WKY (Table 4.12). These channel blockers could not be tested in the 6 month old 
animals due to lack of animal availability. 
 
Figure 4-24 Cumulative concentration response curves to ACh (1nM to 10mM) following 40 
min 100µM L-NAME and 10µM indomethacin incubation control, and + 30µM apamin and 
1µM TRAM-34 (n=4). 
 
Table 4-12 Maximum relaxation and pEC50 of ACh in 3rd order MRAs of 12 week old WKY 
control vessels and vessels incubated in apamin and TRAM-34. All vessels exposed to 
100µM L-NAME and 10µM indomethacin for 40 minutes. 
ACh  Control  Apamin + TRAM-34 
E max (g)
   97.34 ± 0.54
  59.01 ± 10.90** 
pEC50     7.87 ± 0.15        6.28 ± 0.59**
 
Expressed as a % of PE pre-constriction as mean ± S.E.M (n=4).
 
**p<0.01 paired t-test compared with control.
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4.4 Discussion 
PE had greater efficacy in SHR compared with WKY at both age points, yet there 
was no difference in the sensitivity to PE between any of the groups. This 
implied that the SHR had a greater capacity for contraction due to either: 
increased smooth muscle mass; release of other factors that constrict the vessel; 
or a decrease in compensatory relaxation. A possible candidate for this increase 
in contraction would be EDCF, since one mechanism of its release is an increase 
in intracellular calcium in the endothelial cells (Vanhoutte et al., 2005). In the 
12 week old SHR strain where there was difficulty in obtaining CCRCs to ACh due 
to an unstable preconstriction to PE, an alternative approach was attempted to 
examine the effects of indomethacin on the release of endothelial-derived 
factors. Since PE sensitivity was the same in WKY and SHR but PE still elicited a 
greater response in SHR, this suggested it was caused by the release of a 
contractile factor or a lack of compensatory relaxation against the PE response. 
Indomethacin was incubated before the CCRC in the SHR to determine whether 
this reduced the size of the PE response, bearing in mind that indomethacin 
abolished the secondary increase in tone to ACh in the 6 month old SHR- thought 
to be attributed to EDCF. EDCF is a product of arachadonic acid metabolism by 
COX (Vanhoutte & Tang, 2008) and in fact, inhibition of COX by indomethacin did 
significantly reduce the maximal PE-induced response and caused a decrease in 
PE sensitivity in the 12 week old SHR vessels. 
A secondary contraction to ACh was observed in 6 month old SHR after maximal 
relaxation had been achieved. It was presumed to be an endothelium-derived 
contraction and not a direct effect of ACh on the SMCs since this secondary 
contractile response to ACh was abolished by indomethacin which blocks the 
COX enzyme that is involved in the production of EDCF (Vanhoutte & Tang, 
2008). Therefore, this latter contraction at higher concentrations of ACh in the 6 
month old SHR appears to be due to the release of EDCF which is partly 
responsible for the endothelial dysfunction in this strain, combined with a 
reduction in EDHF (Vanhoutte & Tang, 2008). 
In SHR at both age points ACh elicited almost no response following incubation 
with L-NAME and indomethacin, indicating that EDHF was not the prevalent 
relaxing factor in this strain. This was in contrast to the WKY response to ACh     102 
following L-NAME and indomethacin incubation which showed that the tissue was 
still capable of a full relaxation in the presence of these agents which block NO 
and prostaglandins. These data do not necessarily mean that the full relaxation 
to ACh is mediated by EDHF rather than NO in the WKY under control conditions, 
but they do show that when NO production was blocked EDHF was capable of 
fully compensating.  
When indomethacin was present there was no longer a significant difference 
between 6 month old WKY and SHR relaxation in terms of efficacy or sensitivity. 
This suggested that the difference between the strains in control experiments 
was due to a factor produced by the COX enzyme, which was inhibited by 
indomethacin. These data are consistent with other data showing an increased 
release of EDCF in SHR mesenteric vessels compared with WKY (Jameson et al., 
1993); and data showing that indomethacin improved the impaired endothelium-
dependent relaxations in the small mesenteric arteries of the SHR (Luscher et 
al., 1990). 
Carbenoxolone abolished the secondary increase in tension observed in the 6 
month old SHR under control conditions. Also, there was no longer a significant 
difference between the strains at 6 months of age in terms of their relaxation to 
ACh following carbenoxolone incubation: vessels from the SHR no longer had an 
increase in tension in response to higher concentrations of ACh; and the 
endothelium-dependent relaxation in the SHR was now capable of almost fully 
reversing the PE induced preconstriction. This suggested that if the increase in 
tension to ACh in the SHR strain was indeed accounted for by EDCF, as was 
implied by its removal when the COX enzyme was blocked by indomethacin, then 
carbenoxolone was somehow involved in inhibiting its actions. Carbenoxolone is 
a putative gap junction blocker which has been shown to abolish EDHF in rat 
mesenteric vessels (Goto et al., 2002) and so if EDCF were to be transmitted 
through gap junctions in a similar fashion to EDHF then it is feasible that 
carbenoxolone is capable of blocking EDCF also. Indeed, carbenoxolone has been 
shown to reduce endothelium-derived contractions to ACh in the aorta of the 
SHR (Tang & Vanhoutte, 2008). Further studies using the gap junction blocking 
peptides would be of interest to assess whether they also inhibited the 
secondary increase in tension to ACh in the 6 month old SHR. This was not 
feasible in this project due to cost, but would give a better understanding of     103 
whether carbeoxolone’s impediment of EDCF were indeed a consequence of gap 
junction blockade. 
Incubation with carbenoxolone alone did not affect the relaxation to ACh in the 
12 week or 6 month old WKY, but has been shown in publications to inhibit the 
EDHF component of relaxation (Goto et al., 2002). Since there was still a 
complete relaxation to ACh following carbenoxolone incubation this suggested 
that if gap junctions (and hence a possible route of EDHF transmission) were 
blocked, then NO was capable of compensating and eliciting a full relaxation in 
these vessels. To clarify this point, further ACh CCRCs were performed following 
incubation with L-NAME and carbenoxolone in combination to assess whether a 
relaxation to ACh could still be achieved when the NO component of relaxation 
was removed and the putative gap junction blocker was present. In combination 
with L-NAME and indomethacin, carbenoxolone significantly reduced the 
maximum relaxation to ACh. This implied that carbenoxolone had some effect in 
blocking MEGJs, which was only apparent when the NO-mediated component of 
relaxation was removed.  
To ensure that the relaxation to ACh which persisted in the presence of L-NAME 
and indomethacin was a true EDHF response (to refute the possibility that the 
concentration of L-NAME was not sufficient to block NOS), ACh CCRCs were 
performed in the presence of L-NAME, indomethacin, apamin and TRAM-34 in 
combination. Under these conditions the relaxations were significantly reduced 
from the control (L-NAME and indomethacin incubation only), however, the 
relaxation to ACh was not completely abolished at concentrations above 10µM. 
This raised the possibility of the remaining relaxation being an unknown factor, 
independent of NO, prostanoids and hyperpolarisation of the endothelial cells by 
means of opening calcium-activated potassium channels. Alternatively, this 
could be due to incomplete blockade of the calcium-activated potassium 
channels. However, the latter explanation is unlikely considering the 
concentrations of these toxins used in the present study are consistent with 
those used in the literature (Harrington et al., 2007).  
All functional responses were measured as changes in tension on a myograph, 
therefore these results alone did not prove conclusively that the relaxation to 
ACh in the absence of NO was a hyperpolarising factor. To confirm that this was     104 
a hyperpolarising response, the relaxation to ACh was assessed following 
application of 30mM KCl to depolarise the vessel in the presence of L-NAME and 
indomethacin. KCl caused a contraction around 30% of the PE induced 
contraction- thereafter PE was added cumulatively to ensure the preconstriction 
matched that of the control. Under these conditions, ACh did not elicit a 
relaxation, thus suggesting that the control relaxation in the presence of L-NAME 
and indomethacin was caused by a hyperpolarisation of the endothelial cells. 
Under control conditions the concentration of potassium ions is greater in the 
cytoplasm than in the extracellular space, thus the opening of calcium-activated 
potassium channels on the endothelial cells causes an efflux of potassium ions 
down the electrochemical gradient, consequently hyperpolarising the 
endothelial cell. This hyperpolarisation by potassium ion efflux was reinforced 
by the decreased maximum relaxation to ACh in the presence of apamin and 
TRAM-34 in combination. When extracellular potassium ion concentration was 
increased by application of 30mM KCl, the endothelial cells were no longer 
capable of hyperpolarisation, and no relaxation was observed. This lack of 
relaxation to ACh under conditions of high potassium in the presence of L-NAME 
was consistent with other findings (Dora et al., 2003a; Waldron & Garland, 
1994).   
 
 
 
Chapter 5                                                         
Functional responses of saphenous arteries 
from young and old WKY and SHR rats 
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5.1 Introduction 
The saphenous artery has been reported as one which exhibits no EDHF response 
in the adult rat, proposed to be due to a lack of MEGJs (Sandow et al., 2004). In 
this respect the saphenous artery contrasts with the mesenteric arteries which 
are known to have a prominent EDHF component of relaxation (Chapter 4, (Dora 
et al., 2003a; Edwards et al., 1999). Thus, the saphenous artery was chosen in 
this study to compare its functional responses to those of the mesenteric 
arteries where EDHF has a prominent role. The functional responses of 
saphenous arteries from normotensive and hypertensive rats at two age points: 
12 week old and 6 month old, were assessed by wire myography. This was 
intended to elucidate whether there was an EDHF response in the young rat that 
became redundant during ageing owing to the reported decrease in MEGJ 
expression (Sandow et al., 2004). 
5.1.1 Aims 
The aims of this chapter were: 
•  To compare the PE contractile response of 12 week and 6 month old WKY and 
SHR. 
•  To compare the relaxation of 12 week and 6 month old WKY and SHR in 
response to ACh, and the contribution of EDHF, if any, in this relaxation. 
•  To assess the effect of the putative gap junction inhibitor carbenoxolone on 
the ACh relaxation in the saphenous artery. 
5.2 Methods 
Saphenous arteries were myograph mounted as detailed in the General Methods 
chapter. Thirty minutes after the wake up procedure CCRCs to PE were 
constructed. After the return to baseline from washout of the PE curve a rest 
period of 30 minutes elapsed before an ACh CCRC was constructed. All ACh 
CCRCs were performed against a stable plateau of preconstriction of the artery 
with 10µM PE.      107 
In a series of experiments examining the effects of endothelial factors, L-NAME 
and indomethacin; indomethacin; or carbenoxolone were incubated 40 minutes 
prior to the ACh CCRC.  
Due to some relaxations not reaching 50% of PE preconstriction, it was not 
possible to provide accurate pEC50 values for saphenous arteries as a percentage 
of the PE-induced preconstriction. Instead, the pEC50 was expressed as the 
concentration of ACh required to produce half of the maximal relaxation in 
grams.  
Mean data for PE-induced contraction and ACh-induced responses were 
compared using Student’s t-tests or one-way ANOVA, with the use of Bonferroni 
post-tests for all pairwise comparisons. 
5.3 Results 
5.3.1 PE-induced contraction 
Concentration dependent contractions were produced to PE in saphenous 
arteries from both WKY and SHR strains to assess the contractile responses 
(Figures 5.1 and 5.2). The response to PE in the 12 week old SHR was 
significantly greater than that of the other groups tested (Table 5.1), however 
this must be interpreted with caution since there is a small sample size of only 
two. There was no significant difference in the PE contraction of the 6 month 
old WKY and SHR rats, and the 6 month old rats of both strains had a greater PE 
contraction than the 12 week old WKY. 
12 week old SHR had significantly greater pEC50 value than 12 week old WKY, 
and the pEC50 values of PE were significantly higher at 6 months than at 12 
weeks of age in both strains. However, there was no significant difference in 
pEC50 values between strains at the same age point (Figure 5.1 and Table 5.1).     108 
 
Figure 5-1 Cumulative concentration response curves to PE in saphenous arteries of WKY 
and SHR (12 week: WKY n=4; SHR n=2; and 6 month: WKY n=5, SHR n=4). Expressed as 
mean ± S.E.M in grams tension. 
 
 
Figure 5-2 Cumulative concentration response curves to PE in saphenous arteries of WKY 
and SHR (12 week: WKY n=4; SHR n=2; and 6 month: WKY n=5, SHR n=4). Expressed as a % 
of own maximum PE response obtained during CCRC as mean ± S.E.M. 
 
Table 5-1 Maximum response and pEC50 of PE in saphenous arteries of 12 week and 6 month 
old WKY and SHR.  
  WKY  SHR 
PE  12 week    6 month  12 week  6 month 
E max (g)   0.65 ± 0.10
   1.04 ± 0.07**
   1.48 ± 0.07***    0.88 ± 0.09
†††  
pEC50   4.94 ± 0.07   5.92 ± 0.09***
   5.37 ± 0.07***    5.91 ± 0.12
†† 
Expressed as mean ± S.E.M. (12 week: WKY n=4; SHR n=2; and 6 month: WKY n=5, SHR 
n=4). 
** p<0.01, ***p<0.001 compared with 12 week old WKY (unpaired t-test) 
†† p<0.01, 
†††p<0.001 compared with 12 week old SHR (unpaired t-test) 
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5.3.2 ACh-induced responses 
Relaxations to ACh were obtained in a concentration dependent manner in both 
strains at both ages (Figures 5.2 and 5.3). The 12 week old SHR had a 
significantly greater relaxation to ACh (expressed in grams or as a percentage of 
PE preconstriction) than any of the other groups tested. The 12 week old WKY 
and 6 month old WKY and SHR had no significant difference in their relaxation to 
ACh (Table 5.2). The pEC50 values were not significantly different in any of the 
groups (Table 5.2). 
 
Figure 5-3 Cumulative concentration response curves to ACh in saphenous arteries of WKY 
and SHR. (12 week: WKY n=4; SHR n=2; and 6 month: WKY n=5, SHR n=4). Expressed as 
mean ± S.E.M in grams tension. 
 
 
Figure 5-4 Cumulative concentration response curves to ACh in saphenous arteries of WKY 
and SHR (12 week: WKY n=4; SHR n=2; and 6 month: WKY n=5, SHR n=4). Expressed as 
mean ± S.E.M as a % of PE preconstriction. 
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Table 5-2 Maximum relaxation and pEC50 of ACh in saphenous arteries of 12 week and 6 
month old WKY and SHR. 
  WKY  SHR 
ACh  12 weeks  6 months  12 weeks  6 months 
Emax (g)    0.40 ± 0.07     0.58 ± 0.06       0.84 ± 0.11**       0.41 ± 0.07
†† 
Emax (% PE)  50.67 ± 5.66   59.54 ± 7.53   70.27 ± 6.64*     55.53 ± 8.71
††† 
pEC50 (% 
own max) 
 5.90 ± 0.06    5.90 ± 0.07       6.03 ± 0.06      5.99 ± 0.10 
Expressed as mean ± S.E.M in grams tension and as a percentage relaxation of PE-induced 
contraction (12 week: WKY n=4; SHR n=2; and 6 month: WKY n=5, SHR n=4). 
*p<0.5, **p<0.01 compared with 12 week old WKY (unpaired t-test) 
††p<0.01, 
†††p<0.001 compared with 12 week old SHR (unpaired t-test) 
 
5.3.3 ACh Time Control CCRCs 
Time control curves to ACh were performed to show that there was no 
desensitisation of the tissue to ACh on the second curve, and so any differences 
observed after incubation with a drug could be considered a true effect of the 
drug. Time controls were performed for 12 week and 6 month old WKY and SHR 
(Figures 5.5, 5.6, 5.7 and 5.8), and showed no significant difference in either 
maximum relaxation or pEC50 between the first and second curve (Table 5.3, 
5.4, 5.5 and 5.6). 
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Figure 5-5 Comparison of ACh response for control and time control CCRCs in saphenous 
arteries of 12 week old WKY (n=4). Response expressed as % relaxation of PE 
preconstriction mean ± S.E.M. 
 
Table 5-3 Comparison of ACh response for control and time control CCRCs in saphenous 
arteries of 12 week old WKY. 
ACh     1
st curve      2
nd curve 
Emax (% PE)  41.41 ± 11.32  41.75 ± 13.51 
Emax (g)   0.49 ± 0.16    0.38 ± 0.17 
pEC50 (%own max)   6.38 ± 0.32    6.27 ± 0.48 
Expressed as mean ± S.E.M (n=4). 
 
 
Figure 5-6 Comparison of ACh response for control and time control CCRCs in saphenous 
arteries of 12 week old SHR (n=2). Response expressed as % relaxation of PE 
preconstriction mean ± S.E.M. 
 
Table 5-4 Maximum relaxation and pEC50 of ACh in saphenous arteries of 12 week old SHR. 
ACh     1
st curve      2
nd curve 
Emax (% PE)  72.42 ± 17.25  65.57 ± 21.91 
Emax (g)   0.76 ± 0.03    0.85 ± 0.28 
pEC50 (% own max)   6.06 ± 0.08    5.96 ± 0.20 
Expressed as mean ± S.E.M (n=2).     112 
 
Figure 5-7 Comparison of ACh response for control and time control CCRCs in saphenous 
arteries of 6 month old WKY (n=5). Response expressed as % relaxation of PE 
preconstriction mean ± S.E.M. 
 
Table 5-5 Comparison of ACh response for control and time control CCRCs in saphenous 
arteries of 6 month old WKY.  
ACh     1
st curve      2
nd curve 
Emax (% PE)  47.95 ± 6.07  41.14 ± 5.97 
Emax (g)   0.42 ± 0.92    0.32 ± 0.07 
pEC50 (% own max)   5.97 ± 0.15    5.63 ± 0.07 
Expressed as mean ± S.E.M (n=5). 
 
 
Figure 5-8 Comparison of ACh response for control and time control CCRCs in saphenous 
arteries of 6 month old SHR (n=4). Response expressed as % relaxation of PE 
preconstriction mean ± S.E.M. 
 
Table 5-6 Comparison of ACh response for control and time control CCRCs in saphenous 
arteries of 6 month old SHR. 
ACh     1
st curve      2
nd curve 
Emax (% PE)  63.50 ± 13.92  58.20 ± 11.78 
Emax (g)   0.50 ± 0.18    0.44 ± 0.15 
pEC50 (% own max)   5.91 ± 0.20    6.12 ± 0.38 
Expressed as mean ± S.E.M (n=4).     113 
 
5.3.4 Responses to ACh following incubation with agents 
affecting endothelial factors 
Further ACh responses were assessed after incubation with compounds affecting 
various endothelium derived factors to gain a better insight into the mechanisms 
of the ACh response. 
5.3.4.1   L-NAME and indomethacin incubation 
ACh CCRCs were obtained in 12 week and 6 month old saphenous arteries 
following L-NAME and indomethacin incubation (Figure 5.9) to block the 
production of NO and prostaglandins respectively. The relaxation to ACh was 
effectively abolished in both strains at both age points (Table 5.7 and 5.8), and 
pEC50 values could not be calculated due to the lack of a relaxant response. 
 
Figure 5-9 Cumulative concentration response curves to ACh following 40 min 100µM L-
NAME and 10µM indomethacin incubation in saphenous arteries of WKY and SHR (12 week: 
WKY n=6; SHR n=4; and 6 month: WKY n=5, SHR n=6). Expressed as mean ± S.E.M as a % 
of PE preconstriction. 
 
5.3.4.2   Carbenoxolone incubation 
CCRCs were performed in the presence of the putative gap junction inhibitor 
carbenoxolone (Figure 5.10). Carbenoxolone had no significant effect on 
maximum relaxations to ACh or pEC50 values in any of the groups tested (Tables 
5.7 and 5.8).     114 
 
Figure 5-10 Cumulative concentration response curves to ACh following 40 min 100µM 
carbenoxolone incubation in saphenous arteries of 12 week and 6 month old WKY and SHR 
(12 week: WKY n=4; SHR n=1; and 6 month: WKY n=5, SHR n=4). Expressed as mean ± 
S.E.M as a % of PE preconstriction. 
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Table 5-7 Summary of ACh induced responses in 12 week old WKY and SHR saphenous 
arteries following incubation with agents  affecting endothelium derived factors.  
      Relaxation to ACh 
12 week old    n     
Emax (% of PE) 
 
pEC50 
WKY       
   Control  6  38.6 ± 5.76  6.00 ± 0.13 
 + L-NAME and 
indomethacin 
 
6      2.26 ± 1.53***  - 
   Control  4  47.18 ± 21.22  6.21 ± 0.15 
+carbenoxolone 
 
4  58.47 ± 16.25  6.35 ± 0.31 
SHR       
   Control  4  64.87 ± 11.29  6.00 ± 0.12 
 + L-NAME and 
indomethacin 
4       5.43 ± 4.17***  - 
       
   Control  1  73.13 ± 0.00  5.48 ± 0.00 
+carbenoxolone  1  72.90 ± 0.00  5.49 ± 0.00 
***p<0.0001 compared with control (1 way-ANOVA). 
 
Table 5-8 Summary of ACh induced responses in 6 month old WKY and SHR saphenous 
arteries following incubation with agents  affecting endothelium derived factors.  
      Relaxation to ACh 
6 month old   n     
Emax (% of PE) 
 
pEC50 
WKY       
   Control  5  65.82 ± 6.62  5.93 ± 0.22 
 + L-NAME and 
indomethacin 
 
5     10.06 ± 7.18***  - 
   Control  5  74.79 ± 20.05  5.75 ± 0.14 
+carbenoxolone 
 
5  59.87 ± 10.54  6.01 ± 0.21 
SHR       
   Control  4  28.99 ± 10.79  6.09 ± 0.19 
 + L-NAME and 
indomethacin 
4       5.54 ± 2.88*  - 
       
   Control  4  71.23 ± 0.53  5.97 ± 0.10 
+carbenoxolone  4  84.80 ± 8.67  5.96 ± 0.16 
***p<0.0001, *p<0.05 compared with control (1 way-ANOVA). 
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5.4 Discussion 
The significantly higher response to PE in the 12 week old SHR compared with 
the other groups tested may be due to the small sample size of only two rats for 
the 12 week old SHR. There was no significant difference in the maximum PE-
induced contraction in the 6 month old WKY and SHR rats, and the 6 month old 
rats of both strains had a greater PE contraction than the 12 week old WKY. 
PE sensitivity increased with age in the saphenous artery, since pEC50 values 
were significantly higher at 6 months than at 12 weeks of age in both strains. 
There was no significant difference in pEC50 values between strains at 6 months 
of age, however, the SHR had a greater pEC50 value than the WKY at 12 weeks of 
age. 
There was almost no relaxation to ACh following L-NAME and indomethacin 
incubation in any of the groups tested, showing that there was no EDHF response 
in the 12 week or 6 month old saphenous artery. This was consistent with the 
findings of Sandow et al 2004. It would be interesting to assess the EDHF 
response of rats younger than 12 weeks old to determine whether the EDHF 
response was present during development.  
These functional results in the saphenous artery contrast sharply with the 
mesenteric functional experiments where EDHF could compensate under 
conditions when the NOS enzyme was blocked by L-NAME (Chapter 4). In the 
saphenous artery this compensatory mechanism of EDHF relaxation was not 
evident. This may relate to the function of the artery in vivo: where the 
mesenteric is important in controlling peripheral blood pressure while the 
saphenous is more of a conduit artery, hence a strong relaxant response is of less 
importance to its function. In this respect the saphenous artery can be utilised 
as a control for the mesenteric artery since the contribution of EDHF was 
negligible and therefore could be discounted without the use of any 
pharmacological agents. 
Carbenoxolone did not significantly alter the maximum ACh-induced relaxation 
or the sensitivity to ACh in any of the groups tested, implying that gap junctions 
played no role in the relaxant response to ACh in the rat saphenous. The effect     117 
of carbenoxolone incubation on the ACh relaxation was not assessed in 
combination with L-NAME and indomethacin in the saphenous artery (as it was in 
the mesenteric artery) since relaxation was abolished after L-NAME and 
indomethacin incubation in the first instance. The incubation of indomethacin 
alone would have proven useful in this artery to determine if the whole relaxant 
response to ACh was NO mediated or if there was an additional prostanoid 
contribution.  
 
 
 
Chapter 6  Heterocellular Gap Junctional Dye 
Transfer in Pressurised Vessels     119 
6.1 Introduction 
Gap junctional communication allows the passage of current, ions and signalling 
molecules less than 1kDa in size between coupled cells (Evans & Martin, 2002). 
This property can be exploited experimentally to study cells that are thought to 
be in contact by gap junctions by examining dye transfer and its impediment by 
putative gap junction inhibitors.  
Cellular projections traversing the IEL could be viewed by pressure fixing the 
vessels at 70mmHg and staining with the membrane dye FM4-64. Previous work 
in the laboratory has shown that there were less myoendothelial bridges in the 
SHR compared with the WKY at 6 months of age, with 73% of fenenestrae 
containing a bridge in the WKY and only 40% containing a bridge in the SHR 
(Gonzalez et al, unpublished). The existence of a bridge is only a potential site 
for MEGJ formation since the membranes are brought into close enough 
apposition for gap junction formation. Although the myoendothelial bridges 
could be visualised by this membrane staining method, it gave no indication as 
to the presence or function of MEGJs, since these can only be visualised at the 
electron microscope level of resolution: for this reason dye transfer experiments 
were undertaken.  
Heterocellular dye transfer has been studied extensively in the vasculature (Dora 
et al., 1999; Griffith et al., 2002; Little et al., 1995b), but it has not been 
considered in hypertension compared with normotensive controls. It was hoped 
this chapter would elucidate whether the reduction in the ACh relaxation 
response in the mesenteric artery in hypertension (Chapter 4) was due to a 
reduction in heterocellular coupling between the endothelial and smooth muscle 
cells. The decreased fenestrae size (Gonzalez et al., 2006) together with the 
reduction in the proportion of fenestrae containing a myoendothelial bridge in 
the 6 month old SHR suggested there was less possibility for MEGJ formation in 
the hypertensive strain: this may be visually evident as less dye transfer (if the 
transfer is facilitated by MEGJs). 
Early studies examined the homocellular and heterocellular passage of dye from 
injected cells (Little et al., 1995b; Mulvany & Halpern, 1977; Dora et al., 1999). 
This was developed further to examine the transfer of luminally loaded dyes     120 
from the endothelial to smooth muscle cell layers in live vessels on a pressure 
myograph (Kansui et al., 2008; Griffith et al., 2002). The technique of luminally 
loaded dye provided a more physiological approach to studying cellular 
communication where the vessel was intact and pressurised. 
The calcein-AM dye was selected for these purposes because it was cell 
permeable in the non-fluorescent state and on conversion to its fluorescent state 
(calcein) by intracellular esterases, it was rendered cell-impermeable (Griffith 
et al., 2002). This feature meant that following luminal application, any 
fluorescence detected in the smooth muscle cells would presumably be a 
consequence of gap junctional transfer since the fluorescent calcein in the 
endothelial cells would no longer be able to diffuse through the membrane to 
exit. This hypothesis was tested further by examining the effects of gap junction 
blocking peptides on the dye transfer observed. 
6.1.1 Aims 
The aims of this chapter were: 
•  To assess heterocellular dye transfer in mesenteric arteries from both the 
normotensive and hypertensive rats at 12 weeks and 6 months of age to 
compare gap junction function.  
•  To assess the effects of gap junction blocking peptides and carbenoxolone in 
mesenteric arteries from each strain to make inferences about the mode of 
dye transfer from the endothelial to smooth muscle cells (i.e. to test if it was 
gap junction mediated). These results were intended to be correlated with 
the EDHF function in the mesenteric vessels, such that a decrease in EDHF 
may be due to a reduction in MEGJs in the hypertensive strain and hence less 
dye transfer.  
•  To determine whether dye transfer occurs in an artery where there is a lack 
of MEGJs by studying the saphenous artery.     121 
6.2 Methods 
Third order mesenteric arteries and saphenous arteries were set up on the 
pressure myograph system as detailed in the General Methods (Chapter 2). The 
saphenous artery did not maintain a pressure of 70mmHg without leakage 
throughout the course of the experiment and so a pressure of 30mmHg was 
found to be optimal. Vessels exposed to the gap junction blocking peptides 
37,43Gap27 100 µM and 
40Gap27 100 µM were incubated with the peptides for 3 
hours prior to the luminal loading of calcein-AM. The vessel was exposed to 3µM 
calcein-AM luminally under conditions of no flow at 70mmHg for 10 minutes and 
was subsequently washed at a flow 300µL/min for 10 minutes, before a 90 
minute equilibration period elapsed for the dye to de-esterify.  After this 90 
minute period the vessel was pressure fixed at 37ºC with 4% paraformaldehyde 
for one hour and stored in fixative in the dark until imaged. For live imaging 
experiments the same protocol was followed but the vessel was imaged after the 
90 minute incubation rather than pressure fixed. A control vessel was imaged 
under the same laser settings without calcein-AM application to assess the level 
of auto-fluorescent background staining from the argon laser excitation. 
Fixed vessels were slide mounted in a silicone well in glycerol to ensure there 
was no distortion of the vessel wall. They were imaged using a x40 oil immersion 
objective with the argon laser at optimal iris, laser 15% and gain 10%. Z-series 
projections through the vessel wall were captured in 1µm steps to a depth of 
50µm, with a two frame kalman for each plane.  
Live vessels were imaged using a x20 ELWD objective with the argon laser at 
optimal iris, laser 5% and gain 10%. Z-series projections were captured 
identically to the fixed vessels. 
Vessels were counterstained with either Alexa 633 hydrazide or SYTO 61 to stain 
the IEL or the nuclei respectively, and so provide a better orientation of the EC 
and SMC layers.      122 
6.2.1 Image Analysis 
In order to quantify the staining observed by eye, voxel intensities were 
measured from the images acquired from vessels that were fixed following 
calcein-AM exposure and de-esterification in the live pressurised vessel.  
Three regions of interest (ROI) of 100 pixels
2 equating to 56.4µm
2 were selected 
at random from each 50µm Z series. This 3D ROI was separated out into 
endothelial and smooth muscle cell layers and the voxel intensity for each 
individual voxel in the endothelial or smooth muscle cell crop was recorded. This 
produced a readout detailing the actual number of voxels with each value of 
intensity ranging from 1 to 255. Due to the slight difference in depth of each EC 
or SMC crop, it was more informative to express the number of voxels at each 
intensity value as a percentage of the number of voxels in the overall volume. 
The intensities were then grouped in “bins” of 50 to allow comparisons to be 
made between strains and groups as a way of quantifying the brightness of the 
fluorescence observed in each cell layer crop.  
Intensity values ranged from 1 to 255: with 1 being the least intense and 255 
being the most intense staining. This correlated with the pseudo colour of the 
image on the imaging program Amira, ranging from blue being least intense to 
green being most intense (Figure 6.1). 
 
Figure 6-1 Amira intensity scale 
 
Live vessels were imaged using a x20 ELWD objective at Argon laser settings: 
laser 10%, gain 8% and optimal iris 1.2. Fixed vessel imaging produced better 
results than live imaging since the cells were more clearly defined when viewed 
on the x40 oil immersion objective. Examples of live artery imaging are provided 
also, but voxel intensities have not been provided because of the high variability 
observed. Due to the expense of the gap junction blocking peptides, 
carbenoxolone was used in the bath for the live imaging experiments as a 
putative gap junction inhibitor.  
Mean data were compared using a Student’s t-test or one-way ANOVA with 
Bonferroni post-test for all pairwise comparisons.     123 
6.3 Results 
6.3.1 Background staining and optimal conditions 
Analysis of the whole control vessel showed that almost 100% of background 
fluorescence from Argon laser excitation lay in the first intensity bin 1-51 (Figure 
6.2). This established the first intensity bin as “background” staining which was 
subsequently omitted from further analysis. 
 
Figure 6-2 Intensity of autofluorescence in ROI from pressure fixed vessel with no calcein-
AM staining (n=2) 
 
To ensure optimal dye conditions were chosen, a series of different times for 
dye loading were tested. The smooth muscle staining intensity was measured in 
experiments with 5, 7 and 10 minutes luminal calcein-AM incubation (Figure 
6.3).     124 
 
Figure 6-3 Smooth muscle cell staining intensity in pressure fixed vessels luminally loaded 
with 3µM calcein-AM for 5, 7 or 10 minutes. * p<0.05, ** p<0.01, *** p<0.001 compared with 
fluorescence of 10 min exposure in same intensity bin (1 way ANOVA followed by 
Bonferroni post test)(n=2). 
 
10 minutes was found to be the optimal time for calcein-AM incubation, since 
neither 5 or 7 minutes gave sufficient SMC staining (Figure 6.3), with very little 
calcein staining above background levels observed in the smooth muscle cells.  
 
Figure 6-4 Endothelial cell staining intensity in pressure fixed vessels luminally loaded with 
3uM calcein-AM for 5, 7 or 10 minutes (n=2). 
 
Analysis of the endothelial cell staining by one-way ANOVA for each intensity bin 
showed that an increased exposure time to calcein-AM did not affect the 
endothelial cell voxel intensity (Figure 6.4). It should be noted that all of the 
above parameters were measured on pressure fixed vessels.     125 
6.3.2 Fixed Vessel Image Analysis 
6.3.2.1   Dye Transfer in 12 week old mesenteric arteries 
Examples of the endothelial and smooth muscle cell ROI crops for the 12 week 
old WKY depict the distinct shape of the endothelial and smooth muscle cells 
and clearly show that both cellular layers were stained (Figure 6.5). This staining 
has been quantified by voxel intensity (Figure 6.6) and showed that there was no 
significant difference in the endothelial and smooth muscle cell staining in the 
12 week old WKY in any of the intensity bins, with the exception of the smooth 
muscle cells having significantly greater staining than the endothelial cells in the 
53-101 bin. 
 
                EC                SMC 
 
Figure 6-5 Endothelial (left image) and smooth muscle cell (right image) calcein staining in a 
ROI from 12 week old WKY mesenteric artery. 
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Figure 6-6 Endothelial and smooth muscle cell staining in the 12 week old WKY mesenteric 
artery (n=3). * p<0.05 compared with fluorescence of EC in same intensity bin (unpaired t-
test). 
 
Further experiments were performed in the 12 week old WKY to assess whether 
this calcein staining in the smooth muscle cells was a consequence of gap 
junctional transfer. This was done by incubating the vessels with a combination 
of the gap peptides 
37,43Gap27 100µM and 
40Gap27 100µM (GJi) prior to luminal 
calcein incubation. Endothelial and smooth muscle cell staining were assessed in 
these vessels (Figures 6.7 and 6.8 respectively). 
 
 
Figure 6-7 Endothelial cell staining in 12 week old WKY mesenteric arteries with (n=3) and 
without (n=3) gap peptide incubation. 
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Gap junction blocking peptides did not affect endothelial cell intensity since 
there was no significant difference from control values at any of the intensity 
bins (Figure 6.7). However, the gap junction blocking peptides did significantly 
decrease smooth muscle cell staining as compared with the control in the 12 
week old WKY in all intensity bins (Figure 6.8).  
 
Figure 6-8 Smooth muscle cell staining in 12 week old WKY mesenteric arteries with (n=3) 
and without (n=3) gap peptide incubation. * p<0.5, ** p<0.01, *** p<0.001 compared with 
fluorescence of control in the same intensity bin (unpaired t-test). 
 
Figure 6.9 shows an example of this decreased smooth muscle cell staining in 
vessels pre-incubated with the gap junction blocking peptides compared with 
control. When viewed from the adventitial side (Figure 6.9, bottom panels), the 
control vessel has far greater SMC staining than the vessel pre-incubated with 
the gap junction blocking peptides.     128 
                Control                 GJ Blocking Peptides 
 
 
 
Figure 6-9 A 50µm Z-series of calcein staining in 12 week old WKY control vessel (left 
image) and vessel incubated with gap junction blocking peptides (right image). Top panels 
are luminal view with SYTO 61 nuclear stain, bottom panels are adventitial view with SYTO 
61 staining omitted for clarity. 
 
SHR mesenteric vessels showed significantly less staining in the smooth muscle 
cells compared with the endothelial cells under control conditions (Figure 6.10). 
In the SHR, gap junction blocking peptides did not cause endothelial or smooth 
muscle cell intensity to vary significantly from control values in any of the 
intensity bins (Figures 6.11 and 6.12 respectively).     129 
 
Figure 6-10 Endothelial and smooth muscle cell staining in the 12 week old SHR mesenteric 
artery (n=5). *** p<0.001 compared with fluorescence of EC in the same intensity bin 
(unpaired t-test). 
 
 
Figure 6-11 Endothelial cell staining in 12 week old SHR mesenteric arteries with (n=5) and 
without (n=5) gap peptide incubation. 
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Figure 6-12 Smooth muscle cell staining in 12 week old mesenteric arteries with (n=5) and 
without (n=5) gap peptide incubation. 
 
Comparison of WKY and SHR endothelial cell calcein staining under control 
conditions showed no significant difference in staining in any intensity bin 
(Figure 6.13). However, the smooth muscle cell staining in SHR was significantly 
lower in all intensity bins than WKY (Figure 6.14). Examples of the calcein 
staining in WKY and SHR control vessels can be seen in Figure 6.15. 
 
Figure 6-13 Comparison of endothelial cell calcein staining in 12 week old WKY (n=3) and 
SHR (n=5) mesenteric control arteries. 
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Figure 6-14 Comparison of smooth muscle cell calcein staining in 12 week old WKY (n=3) 
and SHR (n=5) mesenteric control arteries. * p<0.5, *** p<0.001 compared with fluorescence 
of WKY in same intensity bin (unpaired t test). 
 
WKY              SHR 
 
Figure 6-15 50um Z-series of calcein staining in control vessels from 12 week old WKY (left 
image) and SHR (right image). 
 
6.3.2.2   Dye Transfer in 6 month old mesenteric arteries 
The same experiments were performed in 6 month old animals to determine if 
the dye transfer varied with age. In the 6 month old WKY control vessels staining 
was significantly greater in the endothelial than in the smooth muscle cells in all 
intensity bins (Figure 6.16).     132 
 
Figure 6-16 Endothelial and smooth muscle cell staining in the 6 month old WKY mesenteric 
artery (n=3). * p<0.05, *** p<0.001 compared with fluorescence of EC in same intensity bin 
(unpaired t-test). 
 
The EC staining in control vessels and vessels pre-incubated with the gap 
peptides from the 6 month old WKY was assessed (Figure 6.17). EC staining in 
vessels pre-incubated with gap junction blocking peptides was not significantly 
different from control vessels at low intensities but was significantly lower than 
controls at intensity bins 153-201 and 203-251. Smooth muscle cell staining in 
vessels pre-incubated with the gap junction blocking peptides was significantly 
less than the control vessels in intensity bins 153-201 and 203-251 (Figure 6.18). 
 
Figure 6-17 Endothelial cell staining in 6 month old WKY mesenteric arteries with (n=2) and 
without (n=3) gap peptide incubation. * p<0.05, ** p<0.01 compared with fluorescence of 
control in the same intensity bin (unpaired t-test). 
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Figure 6-18 Smooth muscle cell staining in 6 month old WKY mesenteric arteries with (n=2) 
and without (n=3) gap peptide incubation. * p<0.05, *** p<0.001 compared with fluorescence 
of control in the same intensity bin (unpaired t-test). 
 
SHR control vessels showed significantly less SMC staining than EC staining in all 
intensity bins above 53-101 (Figure 6.19). The gap junction blocking peptides did 
not significantly alter EC or SMC staining compared with the control in the 6 
month old SHR (Figures 6.20 and 6.21 respectively). 
 
Figure 6-19 Endothelial and smooth muscle cell staining in the 6 month old SHR mesenteric 
artery (n=4).** p<0.01, *** p<0.001 compared with fluorescence of control in the same 
intensity bin (unpaired t-test). 
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Figure 6-20 Endothelial cell staining in 6 month old SHR mesenteric arteries with (n=4) and 
without (n=4) gap peptide incubation. 
 
 
Figure 6-21 Smooth muscle cell staining in 6 month old SHR mesenteric arteries with (n=4) 
and without (n=4) gap peptide incubation. 
 
In comparing the two strains at 6 months of age it was found that the SHR had 
significantly less EC staining than the WKY at intensity bins 153-210 and 203-251 
(Figure 6.22). Also, the SHR had significantly less SMC staining than the WKY in 
all intensity bins above 53-101 (Figure 6.23).     135 
 
Figure 6-22 Comparison of endothelial cell calcein staining in 6 month old WKY (n=2) and 
SHR (n=4) mesenteric control arteries. ** p<0.01, *** p<0.001 compared with fluorescence of 
WKY in the same intensity bin (unpaired t-test). 
 
 
Figure 6-23 Comparison of smooth muscle cell calcein staining in 12 week old WKY (n=2) 
and SHR (n=4) mesenteric control arteries . * p<0.5, ** p<0.01 compared with fluorescence of 
control in the same intensity bin (unpaired t-test). 
 
6.3.3 Live vessel image analysis 
Following the purchase of extra long working distance objectives for the 
confocal microscope it was possible to image the vessels live on the pressure 
system. This was a more physiological approach than imaging the vessels after 
they were pressure fixed.      136 
The staining on the live mesenteric vessels was found to be variable, with no 
consistent profile of staining seen in the controls of 12 week old WKY, 12 week 
old SHR, or 6 month old WKY (Figures 6.25, 6.26 and 6.27 respectively) (no 6 
month old SHR were imaged live due to lack of animal availability). For this 
reason the voxel intensities were not quantified, but the Z series projections of 
the vessels imaged were provided. This technique was first tested on murine 
vessels in preliminary experiments to test the dye staining (Figure 6.24). The 
same experiments were performed on vessels pre-incubated in the putative gap 
junction inhibitor carbenoxolone 100µM in the bath for 40 minutes prior to 
luminal calcein-AM exposure (Figures 6.25, 6.26 and 6.27). Images of the calcein 
staining in live saphenous arteries are provided (Figure 6.28). 
The live murine vessel (Figure 6.24) shows both endothelial and smooth muscle 
cell calcein staining following the luminal application of calcein-AM. In the live 
12 week old WKY this same pattern of endothelial and smooth muscle cell 
calcein staining was also observed in control experiments, although the 
brightness of staining varied considerably between preparations imaged under 
the same conditions (Figure 6.25, left hand pane). Incubation with 
carbenoxolone in the live 12 week old WKY vessels appeared to decrease the 
brightness of smooth muscle cell calcein staining on some occasions (Figure 6.25, 
upper two panels), but not on others (Figure 6.25, lower panel). In the live 12 
week old SHR control vessels the smooth muscle cell calcein staining was not 
consistent between preparations (Figure 6.26, left hand pane), but it did appear 
less bright than in the live 12 week old WKY controls (Figure 6.25, left hand 
pane). Incubation with carbenoxolone did not seem to alter staining compared 
with the controls in the live 12 week old SHR. In the live 6 month old WKY, 
carbenoxolone incubation appeared to decrease the smooth muscle cell calcein 
staining compared with the control (Figure 6.27). The live saphenous artery 
showed calcein staining in the smooth muscle and adventitia (Figure 6.27), 
however the endothelial cells could not be clearly seen in this artery due to the 
thickness of the adventitia.     137 
 
Figure 6-24 Live pressurized 1
st order murine mesenteric artery stained with luminally 
loaded calcein-AM 30µM. 
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                               Live 12 week old WKY 
Control        Carbenoxolone 
 
 
100µm 100µm
 
Figure 6-25 Live pressurised (70mmHg) 3rd order MRA of 12 week old WKY stained with 
luminally-loaded calcein-AM, with (right hand pane, n=3) and without (left hand pane, n=3) 
100µM carbenoxolone incubation. 
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   Live 12 week old SHR 
 
 
Control        Carbenoxolone 
 
 
 
Figure 6-26 Live pressurised (70mmHg) 3rd order MRA of 12 week old SHR stained with 
luminally-loaded calcein-AM, with (right hand pane, n=2) and without (left hand pane, n=3) 
100µM carbenoxolone incubation. 
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   Live 6 month old WKY 
 
 
Control        Carbenoxolone 
 
 
Figure 6-27 Live pressurised (70mmHg) 3rd order MRA of 6 month old WKY stained with 
luminally-loaded calcein-AM, with (right hand pane, n=2) and without (left hand pane, n=2) 
100µM carbenoxolone incubation. 
 
 
Live 12 week old WKY saphenous artery 
 
Figure 6-28 Live pressurised (30mmHg) saphenous artery from 12 week old WKY (n=2, 
images from different animals)     141 
6.4 Discussion 
6.4.1 Fixed Mesenteric Artery Staining 
Calcein-AM incubation was assessed at 5, 7 and 10 minutes luminal exposure and 
endothelial cell staining intensity did not vary significantly between these time 
points. However, neither 5 nor 7 minutes exposure to calcein-AM gave sufficient 
smooth muscle cell staining above background levels. Consequently a 10 minute 
exposure time was chosen for all subsequent experiments.  
In the 12 week old WKY the endothelial and smooth muscle cell staining was not 
significantly different in any of the intensity bins, with the exception of bin 53-
101, showing that calcein was transferred to the smooth muscle cells from the 
endothelium following luminal application of the calcein-AM. In order to 
establish if this smooth muscle cell staining was a consequence of gap junctional 
transfer, the same experiments were performed on vessels pre-incubated in a 
cocktail of the gap junction blocking peptides. The gap junction inhibitors did 
not affect endothelial cell staining in the 12 week old WKY, showing that they 
did not affect the uptake of the calcein-AM. However, the smooth muscle cell 
staining was significantly reduced in the 12 week old WKY after incubation with 
the gap junction inhibitors.  
In contrast to the 12 week old WKY, the 12 week old SHR mesenteric vessels 
showed significantly less staining in the smooth muscle cells compared with the 
endothelial cells under control conditions. The gap peptides did not significantly 
alter either endothelial or smooth muscle cell staining from the control in 12 
week old SHR. This suggested that the small amount of smooth muscle cell 
staining observed in the 12 week old SHR was not a consequence of gap 
junctional transfer and could represent calcein-AM that diffused across the 
endothelial layer escaping de-esterification (thus enabling it to enter the smooth 
muscle cells through the membrane, overriding the need for gap junctional 
transfer).  
Comparison of both strains at 12 weeks of age showed that the endothelial 
fluorescence was not significantly different in any of the intensity bins. This 
demonstrated that endothelial cell uptake of calcein-AM was independent of     142 
strain. However, comparison of the WKY and SHR smooth muscle cell staining at 
12 weeks of age showed that the SHR had significantly less voxels in all of the 
intensity bins above background. This implied that the WKY had greater 
communication between the endothelial and smooth muscle cell layers, since in 
the SHR there was less dye transfer from the endothelium to the smooth muscle. 
In the 6 month old WKY control there was significantly less staining in the 
smooth muscle cells than in the endothelial layer in all intensity bins. This 
implied that the endothelial and smooth muscle cell communication had 
deteriorated with age from 12 week old animals, where there was no significant 
difference between the fluorescence of the two cell layers. The gap junction 
inhibitors cause a decrease in endothelial cell staining at high intensities in the 
153-201 and 203-251 intensity bins. This difference may be accounted for by the 
low sample number in these experiments rather than a direct effect of the gap 
junction inhibitors. The gap junction inhibitors caused a significant decrease in 
smooth muscle cell staining at the high intensity bins 153-201 and 203-251, 
which would suggest that some of the smooth muscle cell staining observed in 
the 6 month old WKY control is a result of gap junctional transfer. 
The 6 month old SHR mesenteric vessels showed significantly less staining in the 
smooth muscle cells compared with the endothelial cells at all intensities above 
101. The gap junction blocking peptides did not significantly affect either 
endothelial or smooth muscle cell intensities in the 6 month old SHR, as was the 
case in the 12 week old SHR. This implied that there were less functional gap 
junctions in the SHR as compared with the WKY since the gap junction blocking 
peptides had an effect in the WKY at both age points but not at either age point 
of the SHR. 
6.4.2 Live Mesenteric Artery staining 
Progressing from the fixed experiments, live vessel imaging was undertaken 
using the newly purchased ELWD objectives. In contrast to the fixed vessels 
which showed consistent staining among preparations of the same group, the 
live imaging was found to have variable results- with strong staining observed 
some days and poor staining others, under the same experimental conditions. 
Analysis of results from these experiments showed high variability from     143 
preparation to preparation and no consistent patterns in staining could be 
established.  
Due to the variable nature of the control vessels in the live imaging experiments, 
no conclusions could be reached from the experiments with carbenoxolone 
incubation. A steady level of fluorescence was not observed in vessels without 
carbenoxolone incubation therefore inferences could not be made about the 
effect of carbenoxolone, even thought it did appear to decrease fluorescence in 
some cases. Also, on occasion, the vessels pre-incubated in carbenoxolone 
appeared to have punctate calcein staining at sites which may potentially be 
MEGJs. Experiments with carbenoxolone pre-incubation may have been more 
conclusive if a concentration of 300µM were used. 
These live imaging results were unexpected after the success of the fixed image 
analysis, since there appeared to be no obvious visual difference between the 
WKY and SHR mesenteric staining at either age point. 
It may be the case that the experimental conditions in the live experiments 
were not suitable to detect subtle differences between the preparations. Some 
vessels were more brightly stained than others but this was not due to the 
imaging parameters which were kept constant. The reason for the variation was 
unknown, but perhaps the live vessel was not as resilient to imaging as the fixed 
vessel, making it is more difficult to obtain clear images, especially on a Z-series 
where multiple layers were scanned. 
6.4.3 Live Saphenous Artery Staining 
Dye transfer was studied in the saphenous artery to assess whether luminally 
loaded dye would transfer to the smooth muscle cells in an artery in which an 
absence of EDHF has been established (Sandow et al., 2004). The saphenous 
artery proved difficult to image on the pressure system due to the thickness of 
the adventitia and the problems encountered getting the vessel to maintain 
pressure. Although the imaging through the saphenous was more difficult than 
the mesentery due to its dense adventitia it was possible on several occasions. 
Smooth muscle cell staining was evident in the saphenous artery where it was 
expected there would be no staining since a functional EDHF response was not     144 
obtained in myography experiments (Chapter 4). Due to the problems 
maintaining pressure in the saphenous artery there may have been calcein-AM 
leakage into the bath, causing its uptake from the adventitial side of the vessel.  
To conclude, these results suggest that the fixed image analysis gave more 
consistent patterns of staining between strains than the live imaging. The 
reasons for this are unclear, but it may be that the fixing process halts any 
further progression of dye, whereas the live vessel is still capable of facilitating 
further dye transfer between cell layers.   
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7.1 Introduction 
Gap junctions are formed by the docking of two connexon subunits, each of 
which are composed of 6 connexin proteins (Segretain & Falk, 2004). Four 
connexin subtypes have been found in the vasculature, namely: Cx37, Cx40, 
Cx43 and Cx45. The distribution of connexins has been shown to vary between 
different vessel types and between layers of the same vessel. 
Connexin expression was studied in normotensive and hypertensive rats to 
determine if there was a difference in expression between the strains, and make 
comparisons with the literature. Cx37 and Cx40 expression is reported to be 
decreased in the endothelial cells of mesenteric arteries of SHR compared with 
WKY at 8 months of age (Kansui et al., 2004). 
Mesenteric and saphenous vessels were chosen as examples of resistance and 
conduit arteries respectively. The saphenous artery was of particular interest 
due to its apparent absence of MEGJs in the adult rat shown by electron 
microscopy (Sandow et al., 2004) thereby implying that there would be no 
connexin staining at the myoendothelial border.  
7.2 Aims 
The aims of this chapter were: 
•  To establish Cx37 and Cx43 distribution in the third order mesenteric artery 
and saphenous artery of 6 month old WKY and SHR. 
•  To compare Cx37 and Cx43 profiles between strains. 
7.3 Methods 
7.3.1 Tissue Preparation 
The mesenteric arcade was removed from the rat and spread flat with the gut 
wall outermost. The gut wall was then cut away from the preparation leaving 
the blood vessels and surrounding fat intact. The superior branch and 
surrounding fat was tied with string and the remaining arterial braches were 
gathered and tied at the distal end so that all vessels in the mesenteric arcade     147 
were arranged in parallel. This mesenteric bundle was pinned out taut on dental 
wax before emersion in fixative. The saphenous artery and adjoining nerve and 
vein were pinned out at either end under tension before emersion in PBS. 
Tissues were washed in 0.1M PB and dehydrated through the series: 70% alcohol 
(2 hours), 90% alcohol (2 hours), absolute alcohol (2 hours) x3, amyl acetate (2 
hours) x3, paraffin wax (4 hours) x2. Tissue embedded in wax was then cryostat 
sectioned at 5µm. 
7.3.2 Immunohistochemistry 
The 5µm cryosections of transverse rings of the fixed tissue were mounted on 
poly-L-lysine-coated slides (Surgipath) and air-dried. Slides were incubated in 
Hydroclear for 15 minutes and dehydrated in decreasing concentrations of 
alcohol. Slides were then heated at 100°C for 10 minutes to remove cross-
linkages and rinsed twice in fresh PBS. Sections were blocked with PBS 
containing 1% goat serum with 0.3% Triton for one hour at room temperature. 
Samples were exposed to Cx37 (Cx37 mouse polyclonal, Alpha Diagnostics, 
dilution 1:200) or Cx43 (Cx43 rabbit monoclonal, Millipore, dilution 1:100) 
antibodies at 4°C overnight. Secondary antibodies of goat anti-mouse conjugated
 
Alexa 488 (Molecular
 Probes; 1:400 dilution) or goat anti-rabbit conjugated Alexa 
546 (Molecular
 Probes; 1:400 dilution) were applied to the Cx37 and Cx43 
samples respectively and incubated for 3 hours at room temperature in a dark 
humidity box. They were then washed twice with PBS and finally with distilled 
water. Control slides were incubated with primary antibody but secondary 
antibody incubation was omitted. Sections were mounted with Fluorsave 
(Calbiochem) and imaged using confocal microscopy.  
In the presence of a peroxidase conjugated secondary antibody, 3,3’-
diaminobenzidine (DAB) produces a brown insoluble precipitate in that is 
insoluble in alcohol in the area of the section where the antibody has bound 
antigen. This process was attempted to see if similar results to the fluorescent 
secondary antibody were obtained.     148 
7.4 Results 
The SHR sections cut were of a poor quality compared with the WKY, and have 
been excluded from the study. 
Control vessels for 6 month WKY (with no secondary antibody for Cx37) were 
imaged at the same laser settings as the vessels incubated in the secondary 
antibody. Control vessels have no punctuate staining, but indicate the level of 
background autofluorescence (Figures 7.1 (a), (b)).  
Immunostaining of Cx37 in the WKY mesenteric arteries was confirmed by DAB 
and fluorescence staining, and revealed expression in the endothelial and medial 
layers (Figure 7.1 (c), (d), (e)). The Cx37 staining was prominent on endothelial 
cells, smooth muscle cells, and at the endothelial smooth muscle cell border 
(Figure 7.1 (c)). Control vessels for Cx37 were imaged at the same laser settings 
and have no punctuate staining, but indicate the level of background 
autofluorescence (Figures 7.1 (a), (b)).  
In contrast to the mesenteric arteries, the saphenous artery did not show 
prominent staining for Cx37 in the media, but did exhibit punctuate staining on 
the luminal border of the endothelial cells, and staining at the adventitia (Figure 
7.2). 
Cx43 staining was not present in the mesenteric (Figure 7.3 (c)) or saphenous 
arteries, even after the trial of several other secondary antibodies, and a higher 
dilution (1 in 50) of the Cx43 primary antibody. To confirm that the Cx43 
antibody staining could be detected in other tissues, it was tested on transverse 
sections of the gut (Figure 7.3 (a), (b)), and there appeared to be some 
punctuate staining in these cells.      149 
 
 
   
Figure 7-1 Cx37 staining in mesenteric vessels of 6 month old WKY rat: (a) and (b) control 
sections lacking the secondary antibody, (c) high power confocal image of artery wall, (d) 
high power confocal image of vein and artery wall, (e) DAB staining of artery wall. 
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Figure 7-2 Staining of Cx37 in saphenous artery of 6 month old WKY rat. Counterstained 
with DAPI nuclear stain. 
 
 
 
    
 
 
Figure 7-3 Cx43 staining (a), and DAPI nuclear counterstain (b), in a transverse section of 
the gut, and absence of Cx43 staining in the mesenteric artery (c).  
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7.5 Discussion 
The results from this chapter are by no means conclusive due to the difficulties 
in obtaining good sections for staining. It was not possible to assess Cx40 
distribution due to time limitations but this would be a subject of further 
interest. Unfortunately the SHR sections were of a poor quality, and staining 
could not be analysed due to only a partial adhesion of the sections to the 
slides. It would possibly have been more informative to use whole-mount 
arteries, or to perfusion fix the animals, but this was out with the consent of our 
Home Office Licence.  
Cx37 showed strong staining in the endothelial and smooth muscle cell layers in 
the mesenteric artery. The profile of Cx37 staining differed in the saphenous 
artery, where punctate staining was observed on the luminal border of the 
endothelial cells and at the adventitia. This is suggestive of a lack of connexins, 
hence gap junctions at the endothelial smooth muscle cell border in the 
saphenous artery. However, these results must be interpreted with caution since 
Cx40 staining has not been assessed. 
Due to an absence of control data, the Cx43 staining seen in the gut could not be 
ruled out as autofluorescence, however, the staining is far brighter than that 
observed in the mesenteric artery at the same laser settings. The lack of Cx43 
staining in the mesenteric arteries is consistent with other studies (Earley et al., 
2004; Hong & Hill, 1998). Hong at al. (1998) found that expression of Cx43 was 
restricted to elastic arteries in the rat, following investigation of 11 different 
artery types.   
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Hypertension is a medical condition in which blood pressure is chronically 
elevated. Around 95% of hypertension is essential or idiopathic hypertension, 
that is, it has no known cause. The remaining 5% of cases are secondary 
hypertension, whereby the high blood pressure is a consequence of another 
condition such as kidney disease or an adrenal medulla tumor. As yet, treatment 
for hypertension is symptomatic; therefore drug treatment is aimed at restoring 
blood pressure to normal levels but does not treat the cause of the 
hypertension. Hypertension has been shown to be associated with an impairment 
of endothelium-dependent relaxation in humans (Panza et al., 1990; Linder et 
al., 1990; Treasure et al., 1992) and in animal models (Luscher & Vanhoutte, 
1986; Clozel et al., 1990). Consequently, the differences in endothelial function 
of normotensive and hypertensive resistance arteries, which are the vessels 
important in determining peripheral blood pressure, are the subject of much 
study. SHR cannot directly replicate the condition of human hypertension, but 
due to difficulty in obtaining human tissue biopsies with appropriate controls, 
SHR and WKY controls are widely used in assessing the effects of elevated blood 
pressure on the vasculature. 
In functional experiments (Chapters 4 and 5), there was almost a full reversal of 
the PE preconstriction by ACh in the SHR, similar to that of the WKY, provided 
the NO component of relaxation was intact. However, if NO production was 
blocked, the relaxation to ACh was very poor in the SHR, owing to a blunted 
EDHF response. The transmission of NO does not require gap junctions since 
sandwich preparations have shown that if smooth muscle was opposed with 
endothelium from another vessel then the smooth muscle was still capable of 
relaxation (Chaytor et al., 1998a). This, coupled with the ability of 
carbenoxolone to reduce the EDHF response in the WKY in the present study, 
would suggest that the decreased EDHF response in the SHR is at least partly due 
to a reduction in MEGJs. The idea that EDHF is dependent on gap junctions 
correlates well with dye transfer experiments (Chapter 6), in which SHR showed 
little smooth muscle cell staining in control experiments. No EDHF response was 
obtained in the saphenous arteries in this study (Chapter 5). This is consistent 
with the theory that EDHF is most important in small resistance arteries 
compared with conduit arteries (Berman et al., 2002; Shimokawa et al., 1996b). 
This most likely relates to the physiological roles of the saphenous and 154 
mesenteric vessels: where the mesenteric arteries are fundamental to blood 
pressure control and therefore require the additional mechanism of EDHF to 
backup NO; and where the saphenous artery is capable of dilation by NO release, 
but its dilation does not have an intervening effect on blood pressure, therefore 
EDHF is not an essential functional component.  
The use of a non-adrenergic contractile agonist would have determined whether 
the increased contractility in the SHR was an adrenergic effect or if it was due 
to a general increase in contractility. Similarly, it would have been useful to 
assess responses to the endothelium-independent vasodilator levcromakalim (a 
direct opener of ATP-sensitive K
+ channels) to ensure that the WKY and SHR 
were capable of similar levels of relaxation, independent of the release of 
endothelial factors. However, no significant difference in the levcromakalim 
response was found between the WKY and SHR mesenteric arteries (Onaka et 
al., 1998). 
The compound Rotigapeptide (ZP123) is reported to increase gap junctional 
communication (Clarke et al., 2006), thereby raising the possibility that the 
reduced EDHF response in the SHR could be restored. The mechanism of action 
of Rotigapeptide is unclear but it has been shown to increase dye transfer in 
myocytes and atrial HL-1 cells where Cx43 is the dominant connexin, without 
modifying the overall level of Cx43 or the phosphorylation status of the protein 
(Clarke et al., 2006). As Cx43 is the dominant connexin expressed in the 
mammalian heart this was a very exciting finding. Acidosis causes conduction 
slowing in Langendorff-perfused guinea pig hearts due to intercellular 
uncoupling, and ZP123 was found to inhibit this conduction slowing during 
acidosis by approximately 60%. However, ZP123 had no effect on conduction 
velocity in the absence of acidosis, suggesting that only gap junctions under 
metabolic stress were targeted. In addition, ZP123 did not affect Na
+ current in 
isolated myocytes, suggesting that the activity of the drug was due to an action 
at gap junctions (Eloff et al., 2003). Rotigapeptide is in Phase II clinical trials for 
ventricular arrhythmias, but has the practical limitation of poor oral availability due 
to enzymatic degradation (Mazzini & Monahan, 2008). In another study, 
Rotigapeptide was found to have no effect on forearm blood flow in man when 
NO production and COX were blocked (Lang et al., 2008), showing that it did not 
enhance the EDHF response in-vivo. It would be interesting to assess 155 
Rotigapeptide in functional myography experiments to determine if it was 
effective in restoring the diminished EDHF response in the SHR in-vitro. Also, 
dye transfer experiments following Rotigapeptide incubation could be performed 
to assess if calcein transfer was increased in the SHR.  
Another potential therapeutic target for the restoration of EDHF in hypertension is 
to selectively target the endothelial IKCa channels which are involved in the initial 
hyperpolarisation of the endothelial cells which is transmitted to the smooth muscle 
as EDHF. This may be a promising field of research, with the drug SKA-31 
documented to have a half life of 12 hours and low plasma binding. SKA-31 was 
shown to potentiate the dilations of carotid arteries from KCa3.1 (+/+) mice but not 
from KCa3.1 (-/-) mice, thus affirming it acted on KCa3.1 channels. In-vivo SKA-31 
lowered the mean arterial blood pressure by 6mmHg in normotensive mice, and by 
12mmHg in angiotensin-II-induced hypertensive mice (Sankaranarayanan et al., 
2009). On the other hand, activation of IKCa channels must be treated with caution 
due to their role of in the proliferation of endothelial cells (Grgic et al., 2005) and 
cancerous cells (Wang et al., 2007). It was also found that in mice, administration 
of TRAM-34 for two weeks significantly suppressed angiogenesis by around 85% 
(Grgic et al., 2005). Similarly, in endometrial cancer cells from human specimens, 
clotrimazole and TRAM-34, two inhibitors of IKCa channels, suppressed the 
proliferation of the cancer cells (Wang et al., 2007). 
A further hopeful approach to the treatment of endothelial dysfunction was to 
target the transient receptor potential vanilloid subtype 4 (TRPV4) channel, which is 
involved in Ca
2+ entry following endothelial stimulation. Indeed, mice deficient for 
the TRPV4 channel exhibit impaired endothelium dependent relaxation to ACh in-
vitro and in-vivo (Zhang et al., 2009). A novel activator of TRPV4, GSK1016790A, 
caused a profound decrease in blood pressure in the three species tested (mouse, 
rat and dog), but this was followed by a profound circulatory collapse and death 
(Willette et al., 2008). The GSK compound had no effect on TRPV4 deficient mice, 
thus affirming its action at TRPV4. 
A class of drugs in common therapeutic use, blockers of the renin-angiotensin-
system, has been shown to have actions improving EDHF in the mesenteric arteries 
of SHR. Enalapril, an inhibitor of the angiotensin-converting enzyme (ACE inhibitor) 
improved the EDHF function in mesenteric arteries of the SHR, but NO-mediated 
relaxation was not altered by this drug therapy (Onaka et al., 1998). A subsequent 156 
study demonstrated that the angiotensin 1 (AT1) receptor antagonist TCV-116 could 
also improve the EDHF response in SHR treated from 8 to 11 months (Goto et al., 
2000). Chronic treatment with the AT1 receptor antagonist candesartan was 
reported to increase Cx37 and Cx40 expression in mesenteric arteries of the SHR, 
where Cx37 and Cx40 expression was significantly decreased in SHR compared with 
WKY (Kansui et al., 2004). Hyperpolarisations to ACh were 30% smaller in the SHR 
than in WKY, but this was restored by enalapril (Ellis et al., 2009). There were also 
fewer MEGJs per endothelial cell in the mesenteric resistance arteries of SHR than 
WKY and fewer of the holes in the IEL had endothelial projections, but neither of 
these parameters were altered by enalapril treatment (Ellis et al., 2009). 
In this study, Cx43 could not be detected in the mesenteric or saphenous 
arteries of the WKY or SHR (Chapter 7). This is consistent with the findings of 
Hong and Hill (1998), where Cx43 was only present in larger elastic arteries such 
as aorta. The immunohistochemical findings in this study were by no means 
conclusive but do give an indication of Cx37 presence in both the endothelium 
and smooth muscle in the mesenteric artery; and the restriction of Cx37 to the 
endothelium and parts of the adventitial-SMC border in the saphenous artery. 
The mesenteric imaging data (Chapter 6) revealed a relationship between EDHF 
function and dye transfer in the mesenteric arteries. Smooth muscle cell staining 
was significantly greater in WKY compared with SHR at both age points, whilst 
endothelial cell staining remained consistent between strains. There was a 
functional EDHF response in the mesenteric arteries at both age points, whereas 
no EDHF response was detected in the SHR at either age. The smooth muscle cell 
staining in the WKY was reduced following incubation with the gap peptides, and 
these gap peptides had no significant effect on the SHR smooth muscle cell 
staining. Dye transfer experiments in the saphenous artery were unsuccessful 
since the dense adventitia made this artery difficult to image. A suitable 
alternative may have been to try another artery documented to be lacking an 
EDHF response, with a thinner wall than the saphenous, such as the renal artery, 
to assess dye transfer. The saphenous artery was chosen in this study due to the 
publication by Sandow’s group detailing the EDHF functional response and 
presence of MEGJs by electron microscopy (Sandow et al., 2004). Renal arteries 
have been reported to have a loss of the EDHF response with ageing from 8 
weeks to 22 months (Bussemaker et al., 2003), therefore dye transfer 157 
experiments in this artery at these two age points would test the robustness of 
the theory that calcein staining is correlated with the EDHF function of the 
vessel.   
It has been demonstrated that different connexin subunits in a gap junction 
affect the channel permeability. Cx26 gap junctions are more permeable to 
lower molecular weight dyes such as Lucifer yellow (MW 457), but are 
impermeable to larger dyes such as Alexa 594 (MW 780) (Nicholson et al., 2000). 
This is likely to have implications for dye transfer studies where the composition 
of the gap junctions has not been considered, such that dye transfer did not 
occur due to the size selectivity of the connexins in the gap junctional pore 
rather than due to an absence of gap junctions. Calcein-AM used in this study 
had a molecular weight of 995, which is narrowly within the limit of gap 
junctional transfer of less than 1kDa. When de-esterified to calcein the 
molecular weight is reduced to 622.5. It would be useful to test another dye and 
assess if it was transferred in a similar fashion. However, the property of 
calcein-AM being converted to its cell impermeable fluorescent form calcein 
made this dye ideally suited to the purposes of this study. 
Gap junctions in the cardiovascular system are formed by connexins 37, 40, 43 
and 45. Cx40 has been localised to endothelial cell borders and to small regions 
at the end of endothelial cell projections passing through the IEL in mesenteric 
arteries of the rat (Mather et al., 2005). Rat aortic endothelia have been shown 
to express Cx40, Cx37 and Cx43; and coronary artery endothelia expressed Cx40 
and Cx37, but lacked Cx43 (Yeh et al., 1998). In microvessels from the brain and 
cremaster of the rat, and arterioles of the hamster cheek pouch, Cx43 and Cx40 
have been found in both the endothelial and smooth muscle cell layers (Little et 
al., 1995a). Cx37 has been found in both the endothelial and smooth muscle 
cells of the rat mesenteric arteries, but Cx43 was not detected in this study 
(Earley et al., 2004). In the rat it has been shown that Cx43 staining was 
observed in the endothelium and media of larger elastic arteries, but in smaller 
muscular arteries such as the mesenteric, hepatic, and tail, Cx43 expression was 
high in the endothelium but absent from the media (Hong & Hill, 1998). 
Recently gap peptides have been developed which are small peptides designed 
to interfere with a specific extracellular region of the appropriate connexin. Gap 158 
peptides cannot be selectively targeted to myoendothelial connexins, since the 
inhibitor is selective only for the connexin subunit, therefore will act on any gap 
junctions where this connexin is present. This has therapeutic implications if a 
viable gap junction inhibitor were to be given systemically, since it would have a 
multitude of undesirable effects on gap junctions in the heart and elsewhere.  
There is some ambiguity about the mode of action of gap peptides and whether 
they are truly specific, so another approach to studying the function of a specific 
connexin in the vasculature is to use transgenic connexin knockout mice. Cx45 
deficient mice die during embryonic development due to severe abnormalities in 
vascular development (Kruger et al., 2000). Cx43 knockout mice die perinatally 
caused by a failure in pulmonary gas exchange due to the obstruction of the 
right ventricular outflow tract from the heart (Reaume et al., 1995). Together 
these studies suggest that Cx45 and Cx43 play an essential role in the 
development of the vasculature and the heart respectively. Cell-specific 
deletion of these connexins rather than a full knockout would perhaps permit 
their functional study. Cx40 knockout mice are viable, and study of these 
animals revealed them to be hypertensive in both anaesthetised and awake 
states, without an alteration in heart rate compared with control mice (de Wit 
et al., 2000; de Wit et al., 2003). In addition to this, a polymorphism within the 
Cx40 promoter has been demonstrated to be associated with an increased risk of 
hypertension in men (Firouzi et al., 2006), thus implying that connexins are 
involved in blood pressure regulation in the human vasculature. The use of 
connexin knockout mice would have aided this study in assessing the EDHF 
response and dye transfer in the absence of a particular connexin.  
It was found that there were significantly more fenestrae in the 12 week old 
WKY compared with the 12 week old SHR, but at 6 months of age there was no 
significant difference in fenestrae number between the strains. This coupled 
with an increase in fenestrae area with age in the WKY is suggestive of the fusing 
of adjacent fenestrae in the SHR. Since there are no genetic differences in the 
amount of elastin between WKY and SHR (Briones et al., 2003), then the smaller 
fenestrae in the 6 month old SHR appears to be a protective mechanism against 
the elevated blood pressure in this strain. It would be interesting to assess the 
fenestrae in SHR given antihypertensive treatment from an early age to see if 
the fenestrae develop in the same way as the WKY if blood pressure was not 159 
excessively high, that is, to determine whether the smaller fenestrae are a 
result of strain (SHR) or pressure. 
In summary, although a unifying hypothesis regarding the relationship between 
EDHF and myoendothelial coupling could not be reached, a number of 
conclusions can be drawn from the studies presented. EDHF function in third 
order mesenteric arteries was shown to be reduced in the SHR compared with 
the WKY, and non-existent in the saphenous artery of either strain. The transfer 
of luminally loaded dye was reduced in the WKY following incubation with the 
gap peptides; and in the SHR compared with the WKY control. These results are 
suggestive of dye transfer, representative of gap junctional transfer, being 
related to the functional EDHF response of an artery. The reduced fenestrae 
area in the SHR mesenteric artery may contribute towards this reduction in EDHF 
and dye transfer, since it provides less opportunity for endothelial and smooth 
muscle cell communication, be it via MEGJs or by diffusion.  
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